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The continuing growth in the demographic of aging individuals in the United States 
creates concern for diseases of aging that are chronic, notably unipolar depressive disorders. The 
high rates of depression in the aging population are a concern because of the strong association 
between late-life depression and cognitive impairment. Poor cognitive functioning is a hallmark 
of aging related neurological disorders, the most prevalent being Alzheimer’s Disease (AD). 
Sleep disorder is a core symptom of depression, and is definitively associated with the 
development of mild cognitive impairment (MCI), the prodrome of AD. MCI is also 
characterized by similar types of sleep disturbance including sleep fragmentation, which consists 
of excessive awakenings during the night that leads to atypical suppression of night-time full 
awakenings and chronic sleep debt that impairs daytime attention and cognition as a 
consequence of poor sleep quality. The main hypothesis of this study is that current or historical 
depression in older adults will be associated with poor sleep quality and cognitive impairment. 
Participants (N=50) from 65-85 years were assessed to determine the impact of 
depression status on sleep disturbance and cognitive variables. Individuals endorsing current 
depression (n=9), history of diagnosed depression but no current depression (n=7), or no current 
depression (n=34) were tested for 7 nights using wrist actigraphy and self-report sleep diaries to 
assess various sleep parameters used to identify sleep disturbance. Memory consolidation was 
probed surrounding one night of sleep using a simple procedural memory task and one-month 
follow-up assessment was used to assess a variety of neurocognitive domains including 
immediate and delayed recall, visuospatial abilities, etc. Results from this study revealed that 
individuals with current depression showed poorer sleep quality (i.e. shorter sleep time, lower 
mean sleep efficiency, longer sleep latency, etc.) and self-reported more sleep disturbances and 
greater daytime dysfunction when compared with individuals with no current depression or 
depressive history (p’s < .05). Results of impairment on cognitive tasks from participants with 
current depression or a history of diagnosed depression were not found. These results provide 
evidence of an association between sleep disturbance and late-life depression. Cognitive 







TABLE OF CONTENTS 
LIST OF TABLES…………………………………………………………………………ix 
LIST OF FIGURES………………………………………………………………………...x 






          
         1.1. Late-Life Depression and Cognitive Impairment are Strongly Associated…….5 
                      
                     1.1.1. Vascular Depression Hypothesis……………………………………...8 
  
                     1.1.2. Amyloid Pathology…………………………………………………....9 
                      
                     1.1.3. Depression in MCI and AD…………………………………………...11 
  
         1.2. Cognitive and Brain Reserve…………………………………………………....13 
  
                     1.2.1. Reserve assessed in research studies………………………………….15 
 
                     1.2.2. The Reserve Threshold Hypothesis…………………………………...16 
  
         1.3. Sleep Disorder in Aging………………………………………………………...18 
  
                     1.3.1. Cognition is Impaired by Sleep Deprivation………………………….19 
  
                     1.3.2. Sleep Disorder as a Risk Factor and Symptom of Depression………...21 
          
                     1.3.3. Sleep and Depression in MCI and AD………………………………...24 
  
         1.4. Hypotheses……………………………………………………………………....25 
                      
             1.4.1. Hypothesis I: Impact of Age and Health………………………………25 
 
                              1.4.1.1. Chronic Health is Associated with Depression Status……….25 
                               
                                 1.4.1.2. Health Deterioration in Aging………………………………..25 
  
          
 iv 
 
1.4.2. Hypothesis II: Depressive Symptoms are Connected to 
       Poorer Sleep Quality…………………………………………………....26 
 
 
1.4.2.1. Depressive Symptoms and Poor Objective Sleep Quality….26 
 
 
1.4.2.2. Subjective Measures of Sleep will Reflect  
Objective Measures………………………………………………….26 
  
         1.4.2.3. Depressive History will Impact Sleep Quality………………..26 
  
                     1.4.3. Hypothesis III: Current Depressive Symptoms Impair Cognition…....26 
                                  
                                 1.4.3.1. Historical Depressive Symptoms Impair Cognition………...27 
  
                       1.4.4. Hypothesis IV: Higher Incidence of MCI in Depressed 
            Older Adults………………………………………………………......27 
 
1.4.5. Hypothesis V: Cognitive Reserve Moderates Levels of Cognitive 




          
2.1. Participants……………………………………………………………………………...28 
  
         2.1.1. Recruitment Sites…………………………………………………………......28 
  
         2.1.2. Inclusionary and Exclusionary Criteria……………………………………….29 
  
         2.1.3. Institutional Review Board Approval…………………………………….......30 
  
         2.1.4. Risks and Discomforts………………………………………………………..30 
  
         2.1.5. Benefits……………………………………………………………………….32 
  
         2.1.6. Confidentiality………………………………………………………………..32 
  
         2.1.7. Compensation………………………………………………………………...32 
          
         2.1.8. Voluntary Participation……………………………………………………....33 
  
2.2. Materials and Measures………………………………………………………………...33 
  
 v 
         2.2.1. Depression Measures………………………………………………………..34 
  
                     2.2.1.1. Center for Epidemiological Studies Depression Scale…………....34 
  
  
                    2.2.1.2. Supplemental Questions on Depressive History……………….....34 
  
         2.2.2. Neurocognitive Measures…………………………………………………...35 
  
                     2.2.2.1. Montreal Cognitive Assessment………………………………......35 
  
                     2.2.2.2. Overnight Procedural Memory Consolidation Task……………....35 
  
                     2.2.2.3. Trail Making Test Part A and B…………………………………...38 
  
                     2.2.2.4. Hopkins Verbal Learning Test-Revised…………………………...39 
  
                     2.2.2.5. Boston Naming Test……………………………………………….39 
  
                     2.2.2.6. Brief Visuospatial Memory Test Revised………………………....40 
          
         2.2.3. Cognitive Reserve Measures……………………………………………...…40 
  
                     2.2.3.1. American National Adult Reading Test………………………...…41 
          
                     2.2.3.2. Vocabulary subtest of the Wechsler Adult Intelligence  
Scale-Third Edition……………………………………………...…41 
                      
                     2.2.4. Sleep Measures……………………………………………………....41 
  
                                 2.2.4.1. SleepMove…………………………………………………42 
  
                                 2.2.4.2. Philips Respironics Actiwatch……………………………..42 
  
                                 2.2.4.3. Pittsburgh Sleep Quality Index…………………………….45 
  
                                 2.2.4.4. Stanford Sleepiness Scale………………………………….45 
  
                                 2.2.4.5. Consensus Sleep Diary………………………………….....45 
  
                                 2.2.4.6. Epworth Sleepiness Scale………………………………….46 
  
         2.3. Study Design and Procedure…………………………………………………...46 
  
                     2.3.1. Participant Recruitment Protocol…………………………………….46 
  
 vi 
                     2.3.2. Sleep Study Visit…………………………………………………...47 
  
                                 2.3.2.1. Informed Consent………………………………………...48 
  
                                  
2.3.2.2. MoCA Administration……………………………………48 
                                  
                                 2.3.2.3. Demographics…………………………………………….48 
                                  
                                 2.3.2.4. Depression Measures……………………………………..48 
  
                                 2.3.2.5. Sleep Measures…………………………………………...49 
  
                                 2.3.2.6. SleepMove Placement…………………………………….50 
  
                                 2.3.2.7. Overnight Memory Consolidation Task Training………...51 
                      
                     2.3.3. Neurocognitive Assessment Visit…………………………………...52 
  
                     2.3.4. Scoring Protocol……………………………………………………..53 
  
                              2.3.4.1. Philips Respironics Actiwatch Data Processing…………...54 
  
                                 2.3.4.2. Memory Consolidation Application Data Processing……..54 
  
         2.4. Data Analysis………………………………………………………………….54 
                      




3.1. Demographic Characteristics………………………………………………………….59 
                      
                     3.1.1. Hypothesis I: Impact of Age and Health…………………………….63 
  
                                 3.1.1.1. Chronic Health is Associated with Depression Status…….63 
  
                                 3.1.1.2. Health Deterioration in Aging…………………………….63 
          
3.2. Sleep Study……………………………………………………………………………64 
  
         3.2.1. Hypothesis II: Depressive Symptoms are Connected to Poorer  
          Objective Sleep Quality……………………………………………..………64 
  
           3.2.1.1. Subjective Measures of Sleep will  
Reflect Objective Measures……………………………………......68 
 vii 
  
           3.2.1.2. Depressive History will Impact Sleep Quality…………...71 
  
          
 
3.3. Neurocognitive Output Measures…………………………………………………….74 
  
                     3.3.1. Hypothesis III: Current Depressive Symptoms  
          Impair Cognition…………………………………………………....74 
  
                                 3.3.1.1. Historical Depressive Symptoms Impair Cognition……....77 
  
         3.4. MCI Diagnosis………………………………………………………………...78 
   
3.4.1. Hypothesis IV: Higher Incidence of MCI in Depressed 
            Older Adults…………………………………………………………78 
 
3.5. Cognitive Reserve……………………………………………………………...79 
  





4.1. Depression & Sleep Parameters………………………………………………..81 
 
4.2. Cognitive Status and Health in Aging………………………………………….83 
  
4.2.1. Health and Depression…………………………………………...…..83 
  
4.2.2. Paradoxical Cognitive Findings……………………………………...84 
          
4.3. Cognitive Reserve……………………………………………………………...86 
  
4.4. Mediational Models……………………………………………………………87 
  






Appendix A. Center for Epidemiological Studies Depression Scale………………………108 
  
Appendix B. Supplemental Questions on Depressive History……………………………..109 
  
 viii 
Appendix C. Montreal Cognitive Assessment…………………………………………...110 
  




Appendix E. American National Adult Reading Test…………………………………....116 
  
Appendix F. Pittsburgh Sleep Quality Index…………………………………………….118 
  
Appendix G. Stanford Sleepiness Scale………………………………………………….119 
  
Appendix H. Consensus Sleep Diary………………………………………………….…120 
  
Appendix I. Epworth Sleepiness Scale…………………………………………………...123 
 
Appendix J. Demographic Questions……………………………………………………..124 
  




















 LIST OF TABLES 
 
Table 1. Overnight Memory Consolidation Variables………………………………36 
 
Table 2. Philips Respironics Actigraphic Output Measures………………………...42 
 
Table 3.           Participant Demographics and Health Characteristics…………………….59 
 
Table 4. Actigraphy Variables for Current Depression vs.  
Control Study 2 Groups…………………………………………………....65 
 
Table 5. Self-Report Sleep Variables in Current Depression vs.  
Control Study 2 Groups……………………………………………………69 
 
Table 6.  Actigraphy Variables for History of Diagnosed Depression vs.  
  Control Study 2 Groups…………………………………………………....71 
 
Table 7.  Self-Report Sleep Variables for History of Diagnosed Depression  














LIST OF FIGURES 
 
Figure 1. Study Protocol Timeline………………………………………………….47 
 
Figure 2. Overnight Memory Consolidation Task Protocol………………………...52 
 
Figure 3. Actigraphy Measure of % Sleep Efficiency in Currently Depressed  
and Non-Depressed (Control Study 2) Groups……………………………66 
 
Figure 4. Actigraphy Measure of Mean Sleep Latency in Currently Depressed  
and Non-Depressed (Control Study 2) Groups……………………………66 
 
Figure 5. Standardized regression coefficients for the relationship between 
current depression status and mean sleep efficiency as mediated  
by MCI status based on MoCA total score…………………….………….67 
 
Figure 6. Standardized regression coefficients for the relationship between 
 current depression status and MoCA Attention score as mediated  














LIST OF ABBREVIATIONS AND ACRONYMS 
  
Aβ amyloid-beta 
ACTH adrenocorticotropic hormone 
AD Alzheimer’s Disease 
aMCI amnestic mild cognitive impairment 
AMNART American National Adult Reading Test 
APOE apolipoprotein E 
BMI body mass index 
BNT Boston Naming Test 
BVMT-R Brief Visuospatial Memory Test-Revised 
CSD-M Consensus Sleep Diary-Modified 
CES-D Center for Epidemiological Studies Depression Scale 
CRH corticotropin-releasing hormone 
EDS excessive daytime sleepiness 
EDS elevated depressive symptoms 
EEG electroencephalogram 
ESS Epworth Sleepiness Scale 
FLAIR fluid attenuated inversion recovery 
 xii 
GLM General Linear Modeling 
HIPAA Health Insurance Portability and Accountability Act 
HPA hypothalamic-pituitary-adrenal 
HSCL Hopkins Symptom Checklist 
HVLT-R Hopkins Verbal Learning Test-Revised 
IRB Institutional Review Board 
MCI Mild cognitive impairment 
MDD Major depressive disorder 
MIRAGE Multi-Institutional Research in Alzheimer’s Genetic Epidemiology 
MMSE Mini-Mental State Examination 
MoCA Montreal Cognitive Assessment 
MRI magnetic resonance imaging 
naMCI non-amnestic mild cognitive impairment 
NFT neurofibrillary tangles 
NREM non-rapid eye movement 
OSA obstructive sleep apnea 
PET positron emission tomography 
PSG polysomnography 
 xiii 
PSQI Pittsburgh Sleep Quality Index 
REM Rapid Eye Movement 
SCID Structured Clinical Interview for DSM-III-R 
SD sleep deprivation 
SSS Stanford Sleepiness Scale 
SWA slow-wave activity 
SWS slow-wave sleep 
TBI traumatic brain injury 
TBM tensor-based morphometry 
TMT Trail Making Test 
WAIS-III Wechsler Adult Intelligence Scale-Third Edition 
WASO wake after sleep onset 
WMH white matter hyperintensities 




The continuing growth in the demographic of aging individuals in the United States 
creates multiple health and economic concerns. The past decade alone has shown increases in the 
population of aging individuals (65-85 years) of over 25% and it is projected to rise in the near 
future as baby boomers enter this age range at rates of ~10,000 individuals per day (Lock et al., 
2017). As individuals grow older, they experience degradation of many health systems with 
primary concern for diseases of aging that are chronic (Cauley, 2012; McNicoll, 2012).  In high-
income countries such as the United States, most of the disease burden falls on chronic 
conditions. In a rank order of disease burden in high income countries compiled in 2001, 
unipolar depressive disorders were rated third highest (Cauley, 2012). The World Health 
Organization estimates that 7% of the general elderly population has unipolar depression (World 
Health Organization, 2016). The high rates of depression in the aging population are a concern 
for a variety of reasons with one important one being the strong association between late-life 
depression and cognitive impairment. Poor cognitive functioning is the hallmark of aging-related 
neurological diseases, the most prevalent being Alzheimer’s disease (AD) (Butters et al., 2008; 
Kirova, Bays, & Lagalwar, 2015).  
 The rapidly increasing aging population produces an extensive demographic of aging 
individuals with Alzheimer’s disease and other dementias not only in the United States, but 
throughout the world (Qiu, De Ronchi, & Fratiglioni, 2007). A reported 13.9% increase of aging 
individuals with dementia, 9.7% of which have AD, and a projected likelihood of diagnoses 
doubling every 5 years after the age of 65 creates an imperative need for further research into 
neurodegenerative disorders (Plassman et al, 2007). In particular, an increased focus on 
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understanding early biobehavioral markers of AD and its prodrome, mild cognitive impairment 
(MCI), is critical for early identification and intervention. MCI refers to decline in cognitive 
ability that is greater than expected for an individual’s age and education level but does not 
interfere with activities of daily life (Petersen et al., 2014). MCI can either be amnestic (aMCI) 
or non-amnestic (naMCI). aMCI is a memory disorder with relative preservation of other 
cognitive domains and is often prodromal to AD. This type of MCI is most commonly associated 
with late-life depression. In naMCI, memory remains intact, but one or more other cognitive 
abilities (e.g. language, visuospatial skills, executive functioning) is significantly impaired and 
can be prodromal to other types of dementia such as: frontotemporal dementia, dementia with 
Lewy bodies, primary progressive aphasia, and Parkinson’s disease (UCI Institute for Memory 
Impairments and Neurological Disorders, 2017). The prevalence of MCI in the United States 
ranges from 12-18% among individuals over the age of 60 years (Tampi et al., 2018). Late-life 
depression and memory impairment have been explored through primarily prospective studies 
(Ganguli, Du, Dodge, Ratcliff, & Chang., 2006; Rapp et al., 2011; Richard et al., 2013), but bear 
further investigation. 
 Late-life depression occurs in older adults ages 65 and older and is defined as “a mood 
disorder with symptoms of sadness, negative self-regard, loss of interest in life, and disruptions 
of sleep, appetite, and energy for more than 2 weeks that affects daily living” (5th ed, DSM, 
American Psychiatric Association, 2013). A strong association exists between late-life 
depression, cognitive impairment, and poor cognitive outcomes, including risk of MCI and 
dementia (Sheline et al., 2006; Saczynski et al., 2010; Liu et al., 2017). The mechanisms linking 
late-life depression to MCI and AD are known to be bidirectional but a definitive answer to 
exactly how they are associated has yet to be discovered. The two most prominent mechanisms 
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linking depression and poor cognitive outcomes, such as MCI, include depression being used to 
reveal or unmask clinical MCI or depression overlapping with clinical MCI. The idea of 
depression revealing or unmasking MCI posits that depression may be a risk factor or prodrome 
to MCI development. Conversely, the idea of depression overlapping with MCI propounds that 
depression may be an additional symptom of MCI. Other factors influencing the association 
between depression and MCI include: genetic susceptibility, environmental factors, depression as 
a reaction to MCI, biological bases, etc. (Barnes, Alexopoulos, Lopez, Williams, & Yaffe, 2006; 
Panza et al., 2009). Regardless of the specific mechanism linking late-life depression and MCI, 
sleep disturbance is included as another important factor to consider that influences both 
disorders. 
 Sleep quality drastically impacts overall health as individuals age, specifically brain 
health and associated cognition (Kryger, Monjan, Bliwise, & Ancoli-Israel, 2004). Aging 
individuals in the United States are at greater risk for sleep disturbance and its prevalence 
continues to increase as individuals grow older (Baldwin et al, 2001). A primary physiological 
component of sleep disturbance is sleep fragmentation, defined as the disturbance of sleep 
maintenance that has a negative impact on daytime cognitive ability (Stepanski, 2002). The 
primary self-reported sleep complaint in older adults is difficulty initiating and maintaining sleep 
(insomnia) which exists as a function of sleep fragmentation (Baldwin et al, 2001; Kryger, 
Monjan, Bliwise, & Ancoli-Israel, 2004).  
Sleep disturbance or sleep disorder is a core symptom of late-life depression. Insomnia 
symptoms and excessive daytime sleepiness (EDS) have been shown to increase the risk of 
developing depressive symptoms (Jaussent et al, 2011). Sleep disturbance, including persistent 
insomnia, may continue even after effective treatment for other symptoms of depression and can 
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put an individual at greater risk for relapse (Nutt, Wilson, & Paterson, 2008; Pigeon et al, 2008). 
Sleep disorder also shows a definitive association with MCI development and diagnosis. Poor 
subjective sleep quality has been shown to be connected to incident cognitive impairment in 
community-dwelling older men (Potvin et al, 2012). In addition, sleep disorder in MCI has been 
found to be strongly connected to current or historical diagnosis of major depression (Naismith et 
al, 2011). 
 As previously noted, prospective studies have been primarily used in research to explore 
the relationship between late-life depression and memory impairment (Green et al., 2003; 
Ganguli, Du, Dodge, Ratcliff, & Chang, 2006; Rapp et al., 2011, Richard et al., 2013). Although 
these types of studies are influential in understanding the relationship between late-life 
depression and memory impairment, they are not useful in finding methods of early detection for 
aging-related neurological disorders. Research exploring the association between late-life 
depression and preclinical markers of cognitive decline, an area that currently presents as a gap 
in the literature, may be useful in developing such methods. This thesis project explores both 
current depressive symptoms and history of depressive symptoms, age-adjusted cognitive 
functioning, and objective and self-report sleep measures in older adults from the community 
with and without diagnosed MCI. A participant community sample that includes cognitively 
normal older adults was used for this study because of my thesis project’s interest in early 
markers of cognitive decline associated with either current or past history of depressive 
symptoms, another area for which there is limited research. Participants with diagnosed MCI, 
collected from the same age cohort and demographics, were included to explore the strength of 
association between the two disorders. Cognitive functioning, measured through a variety of 
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paper and pencil neurocognitive tests, were assessed across a participant sample with varying 
presence and severity of past or present depressive symptoms. 
1.1. Late-Life Depression and Cognitive Impairment are Strongly Associated. 
Major depressive disorder significantly impacts the geriatric population, with 12-month 
prevalence rates of 2.7-5.4% and subclinical rates of 8-10% reported by community-dwelling 
older adults (Dotson, Beydoun, & Zonderman, 2010). Late-life depression is additionally tied to 
considerable cognitive complaints, with 20-50% of older adults with late-life depression 
displaying greater cognitive deficits than expected for their age and education level. Common 
cognitive deficits exhibited in late-life depression, even at a subclinical level, include worse 
performance in processing speed, visuospatial abilities, episodic memory, verbal fluency, and 
executive dysfunction, as well as poor learning and free recall on memory tests (Dotson, 
Beydoun, & Zonderman, 2010). Many times, the cognitive complaints in late-life depression 
progress to poor cognitive outcomes. Having a late-life major depressive episode has been found 
to increase risk of dementia 4- to 6- fold and that risk worsens with more persistent depressive 
symptoms (Lenze et al., 2018). Despite the strong associations found among late-life depression, 
cognitive impairment, and poor cognitive outcomes, the directionality and mechanisms 
underlying this connection are poorly understood.  
Panza et al. (2009) explores various possible mechanisms that may explain this 
association. First, depression has specific neurobiological effects on the brain that may make the 
brain more susceptible to developing neurodegenerative disorders in late-life, namely 
Alzheimer’s Disease (AD), and its precursor aMCI. This mechanism is specifically addressed in 
the reserve threshold hypothesis (Butters et al., 2008; Stern, 2012). Another possibility is that 
there may be an interaction in which depression leads to cognitive decline only in the presence of 
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a genetic susceptibility factor (Barnes, Alexopoulos, Lopez, Williams, & Yaffe., 2006) or other 
vascular or environmental determinants. Environmental determinants of neurodegenerative 
disorders may include diet, viral infections, and exposure to neurotoxins (Grant, Campbell, 
Itzhaki, & Savory, 2002). Vascular factors predisposing depression in MCI and AD are further 
explored in the vascular depression hypothesis (Taylor et al., 2005; Taylor, Aizenstein, & 
Alexopoulos, 2013). Depression may additionally be a reaction to the initial symptoms of MCI. 
It is common for older adults to feel a variety of negative emotions upon first encountering 
cognitive decline or a formal diagnosis of a memory disorder, such as MCI (Lahr, Beblo, & 
Hartje, 2007). Depression may be an early manifestation of clinical MCI. More specifically, 
depressive symptoms may reflect an underlying neuropathological condition that results in 
cognitive decline over time. So, depressive symptoms before clinical cognitive impairment may 
represent an early sign of neurodegenerative disease (Chen, Ganguli, Mulsant, & DeKasky, 
1999). However, the two most common mechanisms linking late-life depression and clinical 
cognitive impairment in research are: 1) depression as a risk factor or a prodromal condition to 
MCI development (Palmer et al., 2007) and 2) depression as an additional symptom of MCI 
(Robert et al., 2008). The many possible mechanisms driving these conditions interrelation are 
not mutually exclusive and bear further investigation.  
Since dementia and depression are often comorbid conditions in older adults, they share 
many of the same features that may make the two disorders hard to distinguish. Wright & Persad 
(2007) explored the neuropsychological and neuropathological correlates that make the two 
disorders similar and dissimilar. Impaired function of the HPA axis is a factor of both dementia 
and late-life depression with the explanation of how this factor connects them being further 
spelled out in the reserve threshold hypothesis (Stern, 2002). The reserve threshold hypothesis 
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will be further explained in a future section. Cognitive deficits in both AD and depression 
include impaired performance on tasks of recall memory, visuospatial skills, and executive 
functioning, however, these deficits may also be explained by decreased levels of motivation in 
depressed older adults. The specific behavioral profile of depressed individuals with symptoms 
of disinterest and apathy may in fact predict those who will eventually develop dementia 
(Berger, Fratiglioni, Forsell, Winblad, & Backman, 1999). For instance, depressed individuals 
that eventually developed dementia often presented with disinterest, lower energy, and 
concentration difficulties in a greater proportion than nondemented older adults (Robert et al, 
2006). In addition, the cognitive deficits in depressed individuals may put non-demented 
depressed older adults at greater risk of developing AD (Devanand et al., 1996; Chen, Ganguli, 
Mulsant, & DeKosky, 1999). Both depression and dementia disorders, particularly AD, in their 
own way create serious economic and health concerns that may be ameliorated by research into 
preventative measures. 
Dementia is estimated to increase to 8.2 million cases in the United States by 2030 
(Lenze et al., 2018). Research into early detection and preventative measures of dementia can 
greatly improve these rates and their economic burden. In fact, if a preventative measure is 
discovered and disseminated by 2025, we could reduce costs of dementia by 30% and have a 
projected cost-savings of $83 billion dollars by 2030 (Lenze et al., 2018). It is important to 
consider that late-life depression significantly impacts the risk for dementia, particularly AD, 
which may further increase the number of demented individuals. Before we begin work on 
exploring possible preventative measures of dementia, namely AD, we must understand how 
late-life depression and AD area associated through a variety of ideas and theories, with the most 
prominent ones being: the vascular depression hypothesis and amyloid beta pathology. 
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1.1.1. Vascular Depression Hypothesis. The vascular depression hypothesis posits that 
cerebrovascular disease may predispose, precipitate, or perpetuate some geriatric depressive 
syndromes (Taylor, Aizenstein, & Alexopoulos, 2013). Vascular depression is considered a form 
of late-onset depression first occurring after age 50 or 60 years. The cognitive profile of this 
form of depression is indicative of fronto-subcortical dysfunction and has clinical features such 
as: psychomotor change, executive dysfunction, apathy, treatment resistance, absence of family 
history, and disability disproportionate to depression severity (Jain & Steffens, 2018). A 
“depression-related dysfunction syndrome” was conceptualized to define the clinical expression 
of this type of depression, characterized by frontal network impairment caused by vascular and 
other aging related factors and describing depressed patients with vascular disease and evidence 
of impairment in networks related to mood and executive function (Alexopoulos, 2001). 
 MRI-defined vascular depression is characterized by the presence of white matter lesions 
(WMLs), or white matter hyperintensities (WMH), on T2 weighted or fluid attenuated inversion 
recovery (FLAIR) MRI (Taylor, Aizenstein, & Alexopoulos, 2013). WMLs are defined as areas 
of demyelinated cells located in the white matter of the brain. The exact effect of WMLs on brain 
dysfunction remains unclear but it helps to define underlying pathology and greater volumes of 
WMLs have been found to be associated with more rapid progression of AD (“Segmentation and 
Quantification of White Matter Lesions”, Radboud University Medical Center, 2018). Late-life 
depression has been found to be associated with greater WMH severity and greater measured 
WMH volumes which may be a potential diagnostic entity of vascular depression and associated 
cognitive deficits/poor cognitive outcomes (Taylor et al, 2005; Taylor, Aizenstein, & 
Alexopoulos, 2013). 
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 1.1.2. Amyloid Pathology. Amyloid-β (Aβ) peptide accumulation in the brain has been 
observed in both sleep disorder, AD, and late-life depression. A variety of molecular and cellular 
changes occur in the brain of a person with AD. The characteristic neuropathological hallmarks 
of the brain of an individual with AD are neurofibrillary tangles and plaques of the Aβ protein 
(Martins et al., 2018). Neurofibrillary tangles (NFT) involve the abnormal accumulation of tau 
protein inside neurons that block the neuron’s transport system, therefore impairing synaptic 
communication between neurons. Accumulation of Aβ protein is the strongest physiological 
correlate of AD, and occurs when there is an abnormally high production of the protein that 
clumps together to form plaques between neurons that disrupt cell function (“What Happens to 
the Brain in Alzheimer’s Disease?”, National Institute on Aging, 2018). Hardy & Selkoe (2002) 
found that individuals with AD had increased levels of Aβ plaques which were associated with 
more severe cognitive dysfunction. Early studies also found that a specific gene present in these 
Aβ plaques known as apolipoprotein E (APOE) was an important genetic risk factor for AD 
(Martins et al., 2018). 
 Accumulation of Aβ plaques are also found in the brains of individuals with late-life 
depression. A pilot study by Li et al. (2017) found increased Aβ accumulation in cognitively 
normal, depressed older adults. Particularly, elderly depressed patients that have experienced a 
lifetime history of depression had a high volume of Aβ accumulation in mood-related areas of 
the brain. This may indicate that depressive history increases the risk of developing AD and may 
even be a prodromal stage to the disorder. Additional research of Aβ plaques in late-life 
depression, lifetime history of depression, and AD/MCI help to support this hypothesis. Through 
the use of neuroimaging techniques such as positron emission tomography (PET) scans and MRI, 
Chung (2018) explored the relationship between lifetime history of depression and late-life 
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depressive symptoms with cortical Aβ levels. Results indicate that older adults with a history of 
depression, compared to those that had never experienced depression, had increased Aβ burden 
that was also greater than those participants that had only experienced late-life depressive 
symptoms. Wu et al. (2018) also sought to explore amyloid pathology and neurodegeneration in 
a sample of depressed adults without dementia. The sample consisted of 63 middle-aged and 
elderly patients with Major Depressive Disorder (MDD) (n = 24 with MCI, n = 39 with normal 
cognition) and 22 non-depressed, control subjects. PET imaging was used to measure cerebral 
amyloidosis and hippocampal volume as biomarkers of neurodegeneration. Results revealed that 
there were significant differences between Aβ burden in control subjects and subjects with MCI 
and MDD (81.8% of control subjects vs. 37.5% of MCI and MDD subjects were Aβ negative). 
In addition, a considerable amount of MCI and MDD subjects (12.5%) exhibited both Aβ 
positivity and hippocampal atrophy compared to that of control subjects (4.5%) and non-MCI 
subjects (5.1%). These results highlight the heterogeneity of neurodegeneration and Aβ 
accumulation in adults with MDD. 
Aβ deposition and sleep disorder also have a significant association. Disruption of the 
sleep-wake cycle, including nighttime awakenings, may directly increase levels of Aβ in the 
brain. This has been found through much research to also be correlated with AD development 
(Rogers et al., 1992; Musiek et al., 2018). One may thus conclude that sleep disorder and 
fragmentation may lead to increased Aβ levels, accelerated cognitive decline, and greater 
incidence of MCI and AD (Rogers et al., 1992; Musiek et al., 2018). Mander et al. (2015) 
conducted a study that explored Aβ deposition and sleep patterns in aging individuals. 
Researchers utilized PET scans to measure Aβ levels, polysomnography to measure sleep 
patterns, and an episodic associative word-pair task to measure cognition. Results indicated that 
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Aβ pathology was associated with decreased slow wave sleep (SWS), the deepest phase of stage 
3 non-rapid eye movement (NREM) sleep, and impaired memory ability. These results may 
provide a functional pathway by which Aβ deposition may contribute to hippocampus-dependent 
cognitive decline in older adults (Mander et al., 2015). 
1.1.3. Depression in MCI and AD. Promising support of late-life depression and 
memory impairment have been found through prospective studies, most notably the Multi-
Institutional Research in Alzheimer’s Genetic Epidemiology (MIRAGE) Study. The MIRAGE 
study is a cross-sectional study exploring the temporal association between prior depressive 
symptoms and development of AD (Green et al, 2003). Genetic and historical information, 
including history of depression, as determined by self-report, was collected over a period of 10 
years from families in which at least one member met criteria for AD (N=4046). Odds ratios, a 
common measure of association between exposure and outcome used in epidemiological studies, 
of AD were estimated in individuals with and without depressive symptoms adjusting for 
covariates, such as genetic susceptibility. Results indicated that there was a significant 
association between depressive symptoms and AD even when depressive symptoms occurred 
more than 25 years before the onset of AD. The strongest association were found in families in 
which depressive symptoms first occurred within one year of AD onset. A modest association 
was still maintained in families that had depressive symptoms occur more than 25 years prior to 
AD onset. Green et al. (2003) cite two likely sources for the depression and AD association. If 
AD onset develops within one year of depression onset, it is likely that depression is prodromal 
or an early symptom of AD. Alternatively, depression is a risk factor when depressive symptoms 
occur greater than one year before AD onset. 
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Richard et al. (2013) also evaluated the association between late-life depression and poor 
cognitive outcomes, such as MCI and dementia. The participant sample included 2160 
community-dwelling older adults, ages 65 and older. Participants completed the Center for 
Epidemiological Studies Depression Scale (CES-D) and clinicians evaluated MCI and dementia 
diagnoses. Follow-up visits occurred 18-24 months after baseline to reevaluate MCI and 
dementia status. Results indicated a significant association between depression and prevalent 
MCI but not incident MCI. Prevalent MCI cases included individuals who had developed or been 
diagnosed with MCI prior to the onset of the study. Conversely, incident MCI cases included 
individuals that were diagnosed with MCI over the course of the study (Alexander, Lopes, 
Ricchetti-Masterson, & Yeatts, 2017). Individuals with comorbid depression and MCI were also 
at greater risk of progressing into dementia. These results suggest that depression accompanies 
MCI but does not precede it. This study supports the idea that late-life depression may be a 
comorbid condition or early symptom of MCI but not a risk factor. Along with the significant 
effect that late-life depression has on cognition, it is important to take into account the effect of 
historical depressive symptoms on cognitive decline and AD development. 
Rapp et al. (2011) conducted a three-year longitudinal study that explored cognitive 
decline over time in a sample of older adults with and without dementia as a function of current 
and historical depressive symptoms. Participants included 313 older individuals, ages 55-105, 
from elderly nursing homes with 61.3% of the study sample suffering from dementia at baseline. 
Results indicated that the presence of major depression, both currently and historically, led to 
accelerated cognitive decline in dementia that was greater than expected for age and education 
level. In addition, Geerlings et al. (2008) explored whether historical and current depressive 
symptoms were associated with increased risk for incident MCI, and its neurobiological effects 
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such as smaller hippocampal and amygdalar volumes. Within the Rotterdam Scan Study, 503 
nondemented older adults between 60 and 90 years of age with reported historical depressive 
symptoms at baseline were used as the participant sample for this study. At baseline, participants 
were asked whether they had experienced a history of depression and if so, the age of onset and 
if they sought medical treatment for their symptoms. Participants were split into three study 
groups: early onset depression (before the age of 60), late-onset depression (at age 60 or older), 
and no depressive symptoms. Volumetric assessment of the hippocampus and amygdala using 
three-dimensional MRI scans were also performed at baseline for all participants. All 
participants were then followed for an average of 6 years to assess development of AD, 
determined by clinicians using the Mini-Mental State Examination (MMSE). Current depressive 
symptoms were assessed over the course of the study using the CES-D. Results showed that a 
total of 134 subjects (26.6%) reported a history of depression at baseline, with 88 individuals 
reporting early onset and 46 individuals reporting late onset. Results also indicated that history of 
depression, particularly early onset depression, increased risk of AD at follow-up independent of 
hippocampal and amygdalar atrophy as well as presence of current depressive symptoms. 
Although progression of cognitive decline into MCI and dementia diagnoses as a function of 
depression appears bleak, one factor that may be protective against this functional pathway of 
declining cognition is cognitive reserve. 
1.2. Cognitive and Brain Reserve. 
 The factors that contribute to making certain aging individuals with certain life histories 
resilient to onset of diseases of aging have been a topic of conversation and study over many 
years. Resilience refers to multiple structural and functional neurological processes that are 
protective of clinical displays of neurodegenerative and other aging-related diseases. Three of 
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these processes that hold deep importance are cognitive reserve, brain reserve, and brain 
maintenance (Stern et al., 2018). 
 Cognitive reserve refers to differences in ability to perform cognitive processes and 
function daily in the face of brain aging, injury, or pathology. An individual’s cognitive reserve 
is not a fixed property and is influenced by interactions between innate biological differences and 
lifetime exposures (Stern, 2002; Stern et al., 2018). There are various sociobehavioral and early-
life factors that may be assessed when estimating cognitive reserve capacity. These include: 
early-life and current general cognitive ability (e.g. IQ), education level, occupational 
complexity, choice in leisure activities, amount of physical exercise, and social engagement. 
Researchers must take residual approaches to quantify cognitive reserve and often use functional 
imaging, participant characteristics (e.g. IQ and educational/occupational attainment), as well as 
cognitive measures that remain intact throughout the lifespan (e.g. reading tests and vocabulary 
assessments) to accomplish this goal (Stern, 2009; Stern et al., 2018). 
 On the other hand, brain reserve pertains to one’s neurobiology (e.g. neuronal 
redundancy, brain and hippocampal size, etc.) and is theoretically used to account for individual 
structural differences in the brain that allows certain individuals to have a delay in experiencing 
clinical and cognitive symptoms in the face of brain aging and pathology (Satz, 1993; Stern et 
al., 2018). Brain reserve is not something that can be measured directly but may still be assessed 
through gross whole-brain measures reflective of premorbid brain volume. These measures 
include intracranial brain volume, measured through MRI, as well as head circumference. Brain 
reserve may be additionally assessed through more specific neurobiological measures such as: 
specific patterns of gray matter volume, cortical surface area, and cortical thickness, as well as 
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PET scan measures of synaptic integrity, or functional synapses without functional damage in 
neuronal transmission, and white matter structural properties (Stern et al., 2018).  
A related but distinct concept to both brain and cognitive reserve is brain maintenance. 
Brain maintenance is defined as a reduction in aging-related brain changes and pathology due to 
genetics or lifestyle. Brain maintenance is also assumed to be modifiable by experience and has 
similar life factors to cognitive reserve that influence its capacity.  Brain maintenance is best 
measured longitudinally to assess the change and preservation of brain morphology through 
many of the same scanning measures used to measure brain reserve (Nyberg, Lodven, Riklundm 
Lindenberger, & Backman, 2012; Stern et al., 2018). Studies have been conducted to measure 
the concept of reserve through its proxy measures that underlie its functionality. 
1.2.1. Reserve assessed in research studies. Education is often a proxy measure used to 
assess cognitive reserve capacity. In previous studies, dementia incidence rates are lower in 
individuals with higher levels of education to be delayed (Stern, 2012; Mungas et al., 2018). In a 
seminal study conducted by Stern et al. (1999), it was found that higher education was also 
associated with more rapid cognitive decline after initial AD or dementia diagnosis. The 
proposed explanation for this surprising finding was that education, a factor that indicates a 
higher cognitive reserve capacity, promotes resilience to pathological brain changes and delays 
clinical dementia symptoms. In turn, cognition is more greatly depleted by the time it is detected 
on neurocognitive measures in higher educated individuals with dementia since its clinical 
diagnosis is so significantly delayed.  
Mungas et al. (2018) sought to further explore the effect of higher education on rates of 
brain atrophy and cognitive decline. Researchers utilized participants from the UC Davis 
Diversity Cohort, a longitudinal study population of aging individuals that was significantly 
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heterogeneous in race/ethnicity and educational attainment. The participant sample for this study 
included 460 older adults that had at least 2 cognitive evaluations to assess domains such as 
episodic memory, semantic memory, executive functioning, and spatial ability, as well as at least 
1 MRI brain scan. For participants that were assessed through 2 or more MRI scans over the 
course of the study, longitudinal structural change and grey matter volume change were assessed 
using tensor-based morphometry (TBM). Results indicated that education alone did not have a 
significant effect on cognitive change over time, however global grey matter change had a large 
significant effect on cognitive decline, with an increased rate of atrophy associated with faster 
cognitive decline. There was also a strong education by grey matter interaction. Grey matter 
atrophy had a stronger impact on cognitive decline in participants with higher levels of 
education. Additionally, the rate of grey matter atrophy increased by 9% per year of education. 
These results indicate that both brain reserve and cognitive reserve, evaluated through proxy 
measures, have a more complicated effect on cognition once clinical symptoms appear than 
initially hypothesized. 
1.2.2. The Reserve Threshold Hypothesis. One pathway proposed to explain the 
connection between depression and cognitive functioning in aging is the reserve threshold 
hypothesis. Reserve is used to account for individual differences in adapting to age-related brain 
pathological changes (Stern, 2012). There are two distinct types of reserve: brain reserve and 
cognitive reserve. 
Cognitive reserve is a functional assessment that focuses on the individual differences in 
efficiency when performing cognitive tasks or information processed. Cognitive reserve is 
protective of AD and related conditions. It indicates resilience to neuropathological damage by 
exploring how the brain utilizes damaged resources (Stern, 2002). Higher levels of intelligence 
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or education are often associated with the ability to sustain greater brain damage without 
functional damage, or a higher cognitive reserve capacity (Stern, 2012). Brain reserve is 
structural and measured mainly by neuronal redundancy. Neuronal redundancy proposes that 
neuronal circuits likely contain more than the minimum number of neurons needed to perform an 
operation. Individuals with greater neuronal redundancy are proposed to be better able to tolerate 
substantial neuronal loss, as occurs in AD or its prodrome, MCI, than those with less redundancy 
before the appearance of clinical symptoms (Satz, 1993). 
The etiology of cognitive decline in aging is poorly understood. One hypothesis is that 
depression may contribute to risk through stress-related neuronal injury and its action on the 
hypothalamic-pituitary-adrenal (HPA) axis (Butters et al., 2008). The HPA axis is the primary 
stress response system. It is activated in response to stressful events, and corticotropin-releasing 
hormone (CRH) is released from the hypothalamus stimulating adrenocorticotropic-releasing 
hormone (ACTH) release from the anterior pituitary gland, which further stimulates cortisol 
release from the adrenal cortex. HPA axis function works through negative feedback inhibition. 
When appropriate levels of ACTH and CRH are reached in the body, cortisol binds to receptor 
cells in the hippocampus (a structure specialized for learning and memory), hypothalamus, and 
anterior pituitary gland, to inhibit the stress system, including cortisol (Tsigos & Chrousos, 2002; 
Murri et al., 2014). In depression, hypercortisolemia or high levels of endogenous 
glucocorticoids are diagnostic (Lupien et al., 1999; Zunszain, Anacker, Cattaneo, Carvalho, & 
Pariante, 2011). Over time in a depressed state, elevated glucocorticoid levels cause lowered 
hippocampal formation volume, reduced metabolism, and eventual atrophy (Rapp et al., 2006; 
Wright & Persad, 2007). Hippocampal atrophy leads to decrease in cognitive/brain reserve and 
AD may ultimately develop (Butters et al., 2008). 
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Depression-related neuronal injury in aging is also associated with cerebrovascular 
disease (Alexopoulos et al, 1997). Ischemia in frontostriatal brain regions accompanies 
cerebrovascular disease. Brain ischemia occurs when there is insufficient blood flow to the brain 
to meet metabolic demand and leads to cerebral hypoxia and brain tissue death (“About Cerebral 
Ischemia”, Columbia Doctors, 2017). Since the frontostriatal brain circuits mediate motor, 
cognitive, and behavioral functions, brain tissue death in these regions can help explain 
executive dysfunction, psychomotor slowing, and resistance to treatment exhibited in late-life 
depression (Alexopoulos, 2006). Brain ischemia in frontostriatal brain regions leads to decline in 
cognitive and brain reserve as well and AD may ultimately develop (Butters et al, 2008). Taking 
into account the role of HPA axis dysfunction and cerebrovascular disease, the reserve threshold 
hypothesis posits that depression causes neuronal injury which lowers cognitive and brain 
reserve and causes cognitive impairment to manifest earlier and more frequently (Butters et al, 
2008). 
1.3. Sleep Disorder in Aging. Individuals in the United States, particularly aging individuals, 
have an increased incidence of sleep disturbance (Baldwin et al., 2001). Sleep disturbance is 
often characterized by sleep fragmentation. Sleep fragmentation, or WASO (wake after sleep 
onset), consists of excessive awakenings during the night that leads to atypical suppression of 
night-time full awakenings and chronic sleep debt as a consequence of poor sleep quality 
(Durmer & Dinges, 2005; Troese et al., 2008; Smagula, Stone, Fabio, & Cauley, 2016; Mander, 
Winer, & Walker, 2017). In fact, the primary sleep complaint reported by aging individuals is 
difficulty initiating and maintaining sleep (insomnia) throughout the night (Baldwin et al., 2001; 
Kryger, Monjan, Bliwise, & Ancoli-Israel, 2004). Sleep architecture in aging is uniquely altered 
in a way that individuals experience decreases in slow wave sleep (SWS) and rapid eye 
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movement (REM) sleep, while there is an increase in stage 1 sleep, nighttime wakefulness, and 
sleep fragmentation (Van Cauter, Leproult, & Plat, 2000; Ancoli-Israel, 2009). This specific 
sleep architecture, namely the presence of increased sleep fragmentation, may ultimately drive 
older adults to experience sleep deprivation. 
Sleep deprivation (SD) is a common plague to modern society, particularly in aging 
individuals, and is created through lack of sleep and/or chronically fragmented sleep that 
produces a number of negative effects on daily functioning (Kilgore et al., 2010). Sleep 
deprivation decreases sleep-related movements which has significant detrimental effects on 
cognitive functioning through deoxygenation of the brain, which is known to limit neural activity 
and plasticity and ultimately lead to brain atrophy (Potts, Rybak, & Paton, 2005; Segers et al, 
2008; Troese et al., 2008; Feldman, Del Negro, & Gray, 2013; Hadanny & Efrati, 2015). 
Prolonged sleeplessness, which leads to SD, has been shown to have significant negative effects 
on perception, concentration, vision, reaction time, and processing speed (Kilgore et al., 2010; 
Orzel-Gryglewska, 2010). In addition, SD is reflected in the arousal system (Hayes, 2002) and 
has been shown through research to have a dose-dependent relationship with reduced daytime 
alertness, impaired executive function, fatigue, and mood problems. Most importantly, sleep 
disturbance is closely linked to a significant reduction in daytime functioning in almost all 
cognitive domains (Hedden, Oh, Younger, & Patel, 2013). 
1.3.1. Cognition is Impaired by Sleep Deprivation. Sleep plays an imperative role in 
promoting higher order cognitive processes such as memory and integration of information, 
mainly through the consolidation of both declarative and nondeclarative memories. Memory 
consolidation is defined as the process of stabilizing a memory after initial acquisition so that it 
is encoded and stored in long-term memory (Walker, Brakefield, Morgan, Hobson, & Stickgold, 
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2002; Walker & Stickgold, 2004; Durmer & Dinges, 2005). Individuals with neurological and 
neurodegenerative disorders, such as MCI, experience higher rates of sleep disorder than healthy 
older adults (Beaulieu-Bonneau & Hudon, 2009) and have a unique pattern of sleep 
fragmentation (Tractenberg, Singer, Cummings, Thal, 2003; Crowley, 2011; McCarter, Lewis, & 
Boeve, 2012; Ju, Lucey, & Holtzman, 2014) that may provide insight into a better understanding 
of cognitive decline in the geriatric community. 
Sleep and circadian disturbance is a key clinical feature of AD, and its prodrome MCI, 
that is typically characterized by frequent daytime napping, increased nocturnal wakefulness, and 
agitation (“sundowning”) with these changes showing direct links to cognitive impairment and 
functional change (Naismith et al., 2010; Geda et al., 2013). Naismith et al. (2010) sought to 
explore the association between sleep-wake disturbances and neuropsychiatric/cognitive 
symptoms and suggested that sleep disturbance may be etiologically linked to neurodegenerative 
disorders as a prodromal, prognostic, or mediating factor. The study sample consisted of 15 older 
adults with naMCI who were administered psychiatric and neuropsychological assessments, 
sleep questionnaires and diaries, and 2 weeks of actigraphy (used to measure WASO and number 
of arousals/wake bouts). Results indicated that a greater WASO was associated with impaired 
attention and executive functioning and increased arousals/wake bouts were associated with 
poorer nonverbal learning and problem solving. These results suggest that sleep-wake 
disturbance, particularly in naMCI, is related to impaired cognitive functioning indicating shared 
neurobiological underpinnings. Subjective poor sleep quality in older adults has also been 
studied in connection with cognitive impairment. 
Potvin et al. (2012) examined the relationship between subjective sleep quality and 1-
year incident of cognitive impairment in cognitively normal men and women. This prospective 
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cohort study included a community sample of 1664 older adults between the ages of 65 and 96 
years old. Sleep quality and cognitive functioning were assessed at baseline using the PSQI and 
MMSE, respectively. Incident cognitive impairment was defined as a follow-up MMSE score 
below the 15th percentile according to normative data and at least 2 points below the baseline 
score. Cognitively impaired participants were then split into amnestic and non-amnestic groups 
according to MMSE delayed recall performance. Results indicated that global PSQI scores were 
significantly associated with incident MCI in men but not in women. In women, sleep 
disturbance and long sleep duration were correlated with non-amnestic and amnestic cognitive 
impairment, respectively. In men, short sleep duration and habitual sleep efficiency were 
associated with amnestic and general incident cognitive impairment, respectively (Potvin et al., 
2012). The results from this study show that subjective sleep quality impairs cognitive 
performance in a similar manner to objective sleep quality. 
Research in both older and younger adults suggest that sleep disturbance is integral not 
only to neuropsychological function, but also to mood. Sleep deprivation and fragmentation, as 
well as insomnia, are associated with a variety of mood changes, as found in large community 
samples, and namely a risk factor for onset and recurrence of depression in older adults (Buysse, 
2004; Cho et al, 2008; Naismith et al, 2010). Through these studies, one can conclude that sleep 
disorder presents as both a prodrome and a symptom of depression in aging individuals 
1.3.2. Sleep Disorder as a Risk Factor and Symptom of Depression. Major depression 
changes objective sleep architecture in a variety of ways. Depressed patients experience 
increased wakefulness, reduced sleep efficiency, increased sleep onset latency, decreased total 
sleep time, decreased SWS, and fragmented sleep (Benca, Obermeyer, Thisted, & Gillin, 1992; 
Nutt et al, 2008). Slow-wave activity (SWA), a marker of homeostatic drive to sleep evaluated 
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by an electroencephalogram (EEG) during non-REM sleep, is also markedly different in 
depressed individuals. SWA is normally highest at the onset of sleep and through the first sleep 
cycle, then diminished through the subsequent sleep cycle as sleep debt is repaid and sleep drive 
declines. In depressed patients, the decrease in SWA throughout the subsequent sleep cycle is 
disrupted, with highest SWA occurring in the second non-REM period. Individuals with 
depression also subjectively report sleep disturbance, with this initial complaint sometimes 
occurring before diagnosis of depression (Argyropoulos & Wilson, 2005; Armitage, 2007). Sleep 
disturbances (e.g. persistent insomnia) can continue even after effective treatment of other 
symptoms of depression and puts an individual at greater risk for relapse (Carney, Segal, 
Edinger, & Krystal, 2007; Dombrovski et al., 2007). Persistent insomnia has been a topic of 
study as not just a symptom but also a significant risk factor for developing depression. 
Sleep disturbance namely, persistent insomnia, is an established risk factor for the 
development of new-onset and recurrent major depressive disorder (Kennedy, Kelman, & 
Thomas, 1991; Brabbins et al., 1993; Mallon, Broman, & Hetta, 2000; Roberts, Shema, Kaplan, 
& Strawbridge, 2000). Research of persistent insomnia and whether it perpetuates MDD has not 
been as fully explored. Pigeon et al. (2008) conducted a longitudinal study to examine the 
relationship between insomnia and continuation of depression and/or dysthymia (e.g. persistent 
depressive disorder) in older adults. The participant sample included older adults over the age of 
60 with depression. Participants were taken from a cohort that participated in Project IMPACT, a 
multi-site intervention study of 1801 elderly patients with MDD and/or dysthymia. Participants 
were assessed on insomnia status using the Hopkins Symptom Checklist (HSCL) at baseline and 
3-, 6-, and 12-month time points and were sorted into study groups (persistent insomnia, 
intermediate insomnia, no insomnia). Depression status was also evaluated at these time points 
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using the 20 depression items on the HSCL and through a Structured Clinical Interview for 
DSM-III-R (SCID). Results indicated that participants with persistent insomnia were 1.8 to 3.5 
times more likely to remain depressed when compared to their counterparts without insomnia. 
This pattern was more robust in participants with MDD as opposed to dysthymia. These results 
suggest that persistent insomnia is not only a risk factor for depression but also serves to 
perpetuate the illness in those that receive standard care for depression (Pigeon et al., 2008). 
Depressed older adults that experience insomnia also suffer from excessive daytime 
sleepiness (EDS) with this association being shown in the few prospective studies that have been 
conducted (Dryman & Eaton, 1991; Livingston, Blizard, & Mann, 1993; Cho et al., 2008; 
Jaussent et al., 2011). Jaussent et al. (2011) sought to explore insomnia and EDS as predictive 
factors for depressive symptoms in community-dwelling older adults. 3824 older adults, ages 65 
or older and free of depressive symptoms at baseline, were taken from the cohort partaking in 
The French Three-City Study, a longitudinal study that spanned across 4 years. Questionnaires 
were used to evaluate insomnia symptoms, EDS, and use of sleep medication. Depressive 
symptoms were assessed at 2- and 4-year follow-up visits using the CES-D. Results indicated 
that insomnia symptoms and EDS each independently increased risk for incident depressive 
symptoms. Poor sleep quality and difficulty in initiating and maintaining sleep were also found 
to be risk factors of incident depressive symptoms. Finally, use of sleep medication was a risk 
factor of incident depressive symptoms, independent of insomnia symptoms and EDS. These 
results indicate that insomnia symptoms, EDS, and use of sleep medication all increase the risk 
for incident depression and therefore may be explored clinically as early indicators of depression 
in older adults (Jaussent et al., 2011).  
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1.3.3. Sleep and Depression in MCI and AD. The link between sleep disorder, 
including self-reported symptoms and objective sleep architecture, and impaired cognition 
resulting in neurodegenerative disorders, such as MCI, is well established (Naismith et al, 2010). 
One factor that may influence the relationship between sleep and cognition is depression, a 
disorder that is also significantly affected by sleep quality. Few studies have considered the role 
that depression plays in the association between sleep and cognition despite evidence that poor 
sleep is closely related to depression (Sbarra & Allen, 2009) and sleep disorder and depressive 
symptoms are both independently associated with cognitive impairment (Riemann, Berger, & 
Voderholzer, 2001; Naismith, Norrie, Lewis, Scott, & Hickie, 2009; Koehler, Thomas, Barnett, 
& O’Brien, 2010; Smagula et al., 2013; Snyder, 2013).  
Mellor et al. (2018) sought to investigate the association of sleep architecture/sleep-wake 
patterns and daytime cognitive performance in older adults with a current diagnosis of MDD. 
The participant sample included 43 older adults, ages 50-78, including individuals that had a 
current clinical diagnosis of MDD (n=10) and those that were not currently depressed (n=33). 
Home polysomnography (PSG), an in-home method used to diagnose a variety of sleep disorders 
by recording brain waves, blood oxygenation, heart rate, breathing, and leg/eye movements, was 
conducted for 2 nights, with each night separated by a week. Patients also wore an actiwatch, a 
non-invasive monitor worn on the wrist that is used to measure sleep-wake cycles, for a total of 
two weeks. A standardized battery of neurocognitive assessments was given to all participants. 
Results revealed that sleep-wake patterns, measured by actigraphy (e.g. actiwatch), were linked 
to vigilance and memory across the entire sample. Specifically, greater WASO was associated 
with slower vigilance (speed) and poorer memory (delayed recall accuracy). There were medium 
to large interaction effects of depression and actigraphic sleep variables (e.g. WASO and total 
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sleep time) in predicting performance on cognitive variables. Significant results linking PSG data 
and depression status were not found. Therefore, this study shows that depression has a 
significant impact on the relationship between sleep-wake patterns (but not sleep architecture) 
and cognition (Mellor et al., 2018). The association between sleep architecture, depression, and 
cognition should still be further explored in future studies. The results found associating sleep-
wake variables and depression with cognition provide exciting possibilities for early intervention 
of cognitive impairment in older adults. Early detection of sleep problems in both depressed and 
non-depressed older adults offers a possible window to provide behavioral or pharmacological 
treatments that may improve cognition (Pace-Schott & Spencer, 2011; Mellor et al., 2018) 
1.4. Hypotheses. 
 Based on the studies and information provided regarding current and historical depressive 
symptoms and sleep parameters, and their effect on pathological cognitive decline in aging 
individuals, the following hypotheses were proposed and tested in this thesis study. 
1.4.1. Hypothesis I: Impact of Age and Health. Current depressive symptoms and/or 
history of clinical diagnosis of depression in a community sample will be associated with age 
and health history. 
1.4.1.1. Chronic Health is Associated with Depression Status. The presence of any 
history of depression in a community sample will be associated with higher incidence of chronic 
health problems including cerebrovascular disease, cardiovascular disease, and diabetes (Lenze 
et al, 2005; Moussavi et al, 2007; Taylor, Aizenstein, & Alexopoulos, 2013). 
1.4.1.2. Health Deterioration in Aging. Older participants will report a greater amount 
of health problems than younger participants across the whole sample, as health deterioration 
corresponds with increased age (Cauley, 2012; McNicoll, 2012). 
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 1.4.2. Hypothesis II: Depressive Symptoms are Connected to Poorer Sleep Quality. 
Participants with current depressive symptoms will show poorer sleep quality than participants 
without current or historical depression. 
 1.4.2.1. Depressive Symptoms and Poor Objective Sleep Quality. Participants with 
current depressive symptoms will show poorer objective sleep quality, as measured through 7 
consecutive days and nights of wrist actigraphy, than participants without current or historical 
depression (Naismith et al., 2009, 2011). 
 1.4.2.2. Subjective Measures of Sleep will Reflect Objective Measures. Through 
subjective measures of sleep quality (e.g. Epworth Sleepiness Scale, Stanford Sleepiness Scale, 
Pittsburgh Sleep Quality Index), participants with current depressive symptoms will report a 
greater amount of sleep problems than participants without current or historical depression 
(Foley et a., 1995; Becker, Jesus, Joao, Viseu, & Martins, 2017). 
 1.4.2.3. Depressive History will Impact Sleep Quality. Participants with a history of 
diagnosed depression will show and report more sleep problems than participants without a 
depressive history, as persistent insomnia may continue even after effective treatment of 
depression (Carney, Segal, Edinger, & Krystal, 2007; Dombrovski et al, 2007). 
 1.4.3. Hypothesis III: Current Depressive Symptoms Impair Cognition. Aging 
participants who display symptoms of current depression will perform more poorly on 
neurocognitive testing (e.g. paper and pencil neurocognitive assessments and overnight memory 
consolidation task) than participants without current or historical depressive symptomatology 
(Lenze et al., 2018). 
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 1.4.3.1. Historical Depressive Symptoms Impair Cognition. Aging participants who 
report a history of diagnosed depression will perform more poorly on neurocognitive testing than 
participants without depressive history (Rapp et al., 2011). 
 1.4.4. Hypothesis IV: Higher Incidence of MCI in Depressed Older Adults. Aging 
participants who display symptoms of current depression will have a higher incidence of aMCI, 
as late-life depression is associated with poor cognitive outcomes such as neurodegenerative 
disorders (Sheline et al., 2006; Dotson et al., 2010; Lenze et al., 2018). 
1.4.5. Hypothesis V: Cognitive Reserve Moderates Levels of Cognitive Impairment. 
Cognitive reserve (measured through education level and IQ correlates such as the vocabulary 
subtest of the WAIS-III and AMNART) will have a protective or moderating effect on 
neurocognitive impairment in participants with or without positive current or historical 
















 A sample of aging individuals were recruited as part of an externally (National Institute 
of Health; NIH) funded sleep monitoring project (number R44AG059536-01). University of 
Maine’s Institutional Review Board (IRB) approved this study in which participants, ages 65 to 
85 years, were recruited from the greater Bangor, Maine area (within 40 minutes of Bangor). 
Participants diagnosed with MCI (n=12) were referred by Dr. Clifford Singer, at the Mood and 
Memory Clinic at Northern Lights Acadia Hospital in Bangor, Maine. HIPAA (Health Insurance 
Portability and Accountability Act) acceptance for this study was obtained in order to allow 
researchers to use clinical reports made prior to assessment to determine symptomology and 
diagnosis only for patients referred from the Mood and Memory Clinic. A socio-
demographically similar, but undiagnosed, group of participants (n=38) were accumulated 
through distribution of flyers in the aging community and through area agencies. In addition, Dr. 
Lenard Kaye, director of the University of Maine Center on Aging, provided contact information 
for older adults that had expressed interest in participating in research studies. All participants 
were given information over the phone and at the time of consent, in person, during the study 
visit. Both the MCI-diagnosed and undiagnosed participant groups were matched on 
sociodemographic and health characteristics, with the difference being the clinical diagnosis of 
MCI. 
 2.1.1. Recruitment Sites. All participants with clinical diagnosis of MCI were recruited 
from the Mood and Memory Clinic at Northern Light Acadia Hospital in Bangor, Maine led by 
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chief geriatric psychiatrist, Dr. Singer. The Mood and Memory Clinic is a geriatric psychiatry 
facility catering to accurate diagnosis of common psychiatric disorders in aging. 
 Additional participants reached out to our participant study staff via email or phone upon 
seeing a study flyer. Facilities where flyers were placed include, but are not limited to, Eastern 
Area Agency on Aging, Dirigo Pines, Winterberry Heights Assisted Living and Memory Care, 
Sunbury Village, Bradford Commons, Edward Ernst Manor, and Ellen M. Leach Memorial 
Home. These individuals could contact us through the contact information provided on the study 
flyer. Brief presentations were given to communities of older adults to give additional 
information on this study and to answer questions, during which study flyers were distributed. 
Dr. Lenard Kaye, heads the University of Maine Center on Aging, a community center offering 
various services and programs to aging individuals while promoting research, education, and 
training to individuals in geriatric research and care. The center keeps a large database of names 
and contact information of local older adults interested in participating in research studies. 
Individuals on this list, that were located in the Greater Bangor area, were contacted over the 
phone to determine interest and eligibility for the study. Finally, aging individuals reached out to 
our study team via email following media coverage of our project through the Bangor Daily 
News newspaper and various local news stations. 
 2.1.2. Inclusionary and Exclusionary Criteria. Participants were prescreened for initial 
eligibility criteria including age and physical and mental health status. Inclusionary criteria for 
this study includes male or female participants who are between the ages of 65 and 85 years, live 
independently in the community, are English speaking, and possess adequate vision with 
correction to read. For the MCI group, MoCA score <26 (inclusive), with a delayed recall subtest 
score of 0 or 1 out of 5; Clinical Dementia Rating score of 0.5; normal circadian entrainment to 
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nighttime sleep hours; and decision making capacity to consent to research participation is 
required. For the Comparison group, normal cognition for age (MoCA ≥ 26) and no history of 
sleep-related disorders, periodic leg syndrome, hypnotic/psychotropic medication changes, and 
significant neurological, medical, or psychiatric disorder other than depression are inclusionary 
(drug/alcohol abuse >5 years ago is allowed). Participants in both groups have varying levels of 
depressive symptoms and could be taking medication for their depression, but are labeled as 
having current depressive symptoms and a positive history of depression. Exclusionary criteria 
for the MCI group include normal cognition for age (MoCA ≥ 26 or CDR=0), dementia 
(MoCA< 15 or CDR ≥1), non-amnestic MCI, evidence of another psychiatric or medical 
disorder that may be a cause for MCI (e.g. partial list: more than one cerebral infarct, poorly 
controlled diabetes, hypothyroidism, parkinsonism, parasomnia or REM sleep disorder, 
developmental disability, etc.); acute symptom onset; restless or periodic leg syndrome; hypnotic 
or psychotropic medication change; active bipolar disorder or other psychotic disorders (e.g. 
schizophrenia, delusional disorder, schizotypal personality disorder, schizoaffective disorder, 
etc.); drug/alcohol abuse ≤5 years ago (self-report). 
 2.1.3. Institutional Review Board Approval. This project achieved approval from the 
University of Maine’s IRB, with a Business Associate Agreement (BAA) between the University 
of Maine and Northern Light Acadia Hospital. This study fulfills all requirements for Health 
Insurance Portability and Accountability Act (HIPAA) compliance. 
 2.1.4. Risks and Discomforts. Risk to a participant who is from a vulnerable population 
of cognitively impaired persons and some who are depressed has been carefully considered for 
this study. First, special consideration was taken if a participant presented with severe depressive 
symptoms (e.g. a score of ≥24 on the CES-D). To ensure these participants were able to get 
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appropriate help, contact information was provided on the consent form to community resources, 
most notably the Maine Crisis Hotline and the Geriatric Mental Health and Neuropsychiatry 
Program at Acadia Hospital. All depressive measures were reviewed after completion of the 
study on that day. Follow-up communication via email or phone encouraging participants to 
contact available resources and what those resources were was done that day if participants 
showed severe depressive symptomology or presented as a danger to themselves or others. 
Referrals and follow-up communication were completed according to the standards provided on 
the University of Maine IRB website. Contact information of the participant was collected before 
the onset of the study as a component of the informed consent. In order to insure the cognitively 
impaired person was adequately relayed information on participation, all study information was 
explained in layman's terms by both the cognitively impaired person’s physician and the study 
stuff. All questions were answered and participants who wished to have a caretaker/case 
manager/family member/friend assist in communication with researchers were encouraged to do 
so. Though there were no physical risks, one issue may be the equipment of the sleep study in the 
bedroom. There is very little equipment that remained in the home overnight (a small box for 
wireless data collection placed at the foot of or underneath the bed, the mattress sheet 
unobtrusively below the standard bed-sheet, the tablet for testing, and the Actiwatch device) and 
no complaints were relayed from participants regarding discomfort or annoyance of equipment. 
In regards to the 60-minute neurocognitive testing, risks were limited to time, inconvenience, 
fatigue, and possible frustration due to the nature of the testing. Researchers provided frequent 
breaks and the option to discontinue testing at any point without loss of compensation if the 
participant showed discomfort or fatigue. Researchers rescheduled discontinued testing if desired 
by the participant. 
 32 
 2.1.5 Benefits. As a participant in this study, individuals may discover information about 
their sleep, mood, and cognitive performance, as tested in this research. The results of testing 
will be revealed and interpreted for participants in a thank-you letter after the study is completed, 
with the caveat that these results are for research purposes only. If additional information is 
requested, participants can meet with a researcher to discuss the findings of the study in general, 
and their individual participation. It is also a benefit to contribute to a better understanding of the 
association between late-life depression and neurocognitive functioning in aging and support 
future work toward early detection of aging-related neurological disorders and possible 
minimization of further cognitive decline. 
 2.1.6. Confidentiality. Participant data was de-identified when any data reached the 
laboratory and was instead linked to a study number. The link between data and identifying 
information (i.e. name, address, etc.) is encrypted through a double password method for 
information stored on internet drive, and a hard copy is maintained in a locked file cabinet in a 
locked lab room, ensuring named investigators are the only ones with access to the files. The key 
for the filing cabinet is kept in a separate, locked lab room to provide increased insurance that all 
information is secure. All deidentified data collected in this study will be kept indefinitely 
according to NIH guidelines. The identification key will be protected until March 1, 2028 
allowing adequate time for data collection and potential follow-up studies. 
 2.1.7. Compensation. Participants had a chance to earn up to $150 total for completion 
of this research study. Compensation for the completion of the two-night sleep study was a $100 
Visa gift card and compensation for the completion of the neurocognitive follow-up assessment 
was a $50 Visa gift card. If individuals withdrew before the start of the assessment, 
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compensation was not provided. However, if testing was discontinued due to fatigue and the 
participant did not want to reschedule then full compensation was provided. 
 2.1.8. Voluntary Participation. Participants were informed during initial communication 
about the study and at the time of informed consent that participation was entirely voluntary and 
the participant had a right to decide whether or not he/she chooses to participant in the study and 
may discontinue testing at any time during the course of the study. The theme of voluntary 
participation was repeated and emphasized to ensure participants fully understood the rights they 
had as a participant and that participants did not feel any pressure from the researchers to 
participate or complete assessments. 
2.2 Materials and Measures. 
 All participants were assessed using multiple IRB approved measures and methods used 
for assessing current and historical depressive symptoms, neurocognitive status, and sleep 
parameters, outlined below. This study was broken into two parts, Study 1 (pilot study; N=18) 
and Study 2 (N=32). 
 Study 1 was the pilot study for our lab’s mattress device (not a component of this thesis), 
conducted from Fall 2016-Fall 2017, and had some protocol differences. Most notably, 
depression was not a focus in the pilot study and participants were only asked a question about 
current depression (binary: yes/no) on the demographic interview with no measures assessing 
depression severity or history of diagnosed depression. In addition, cognitive reserve proxy 
measures were not included in the one-month neurocognitive follow-up for study 1 participants. 
All other self-report sleep, actigraphy, overnight memory consolidation, and one-month follow-
up neurocognitive measures were identical between studies. The primary reason for inclusion of 
Study 1 participants in analyses was to have a greater n for the current depression group. 
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 Study 2 is an NIH Phase II study on our lab’s mattress device that has been ongoing since 
March 2019. My thesis project on depression status in older adults has been folded into this 
study. Depression measures (CES-D, supplemental questions on depressive history) and 
cognitive reserve proxy measures (vocabulary subtest of the WAIS-III, AMNART) have been 
added to protocol. All other self-report sleep, actigraphy, overnight memory consolidation, and 
one-month follow-up measures are identical between studies. To keep groups as similar as 
possible, current depression group for analyses were made only by endorsement of current 
depression. History of diagnosed depression was only assessed in Study 2. 
2.2.1. Depression Measures. Depression measures were used to assess both current and 
historical depressive symptoms in Study 2. These measures are used to 1.) run exploratory 
analyses between sleep and cognitive variables across depression scores on CES-D and 2.) group 
participants into study groups for historical depression analyses. 
2.2.1.1 Center for Epidemiological Studies Depression Scale. The Center for 
Epidemiological Studies Depression Scale (CES-D) is a brief self-report questionnaire on 
depressive symptoms. Participants were instructed to rate how often they felt a certain way 
during the past week by checking one of four boxes: rarely or none of the time (less than 1 day), 
some or little of the time (1-2 days), occasionally or a moderate amount of time (3-4 days), and 
most or all of the time (5-7 days) (Radloff, 1977) (see Appendix A). This measure has been 
successfully used to measure depression in older adults mainly due to its brief format and low 
levels of cognitive burden (Andresen, Malmgren, Carter, & Patrick, 1994; Lewinsohn et al, 
1997). 
2.2.1.2 Supplemental Questions on Depressive History. Participants were asked a 
number of supplemental questions assessing depressive and psychiatric history designed 
 35 
specifically for use in this study (see Appendix B). The supplemental questions were utilized to 
establish if a participant had a history of clinical depression and to learn more about that history. 
All questions were delivered in a verbal interview with the participant. 
2.2.2. Neurocognitive Measures. A battery of validated standardized neurocognitive 
assessments was used to test current cognitive functioning in various domains, including, but not 
limited to: visuospatial, episodic and working memory, and verbal learning. A novel procedural 
memory task was also utilized in testing to assess overnight memory consolidation. Participants 
in both Study 1 and Study 2 were assessed on all neurocognitive measures.  
 2.2.2.1. Montreal Cognitive Assessment. The Montreal Cognitive Assessment (MoCA) 
is a brief (1 page, <10 minutes) screening instrument for MCI and mild AD assessing seven areas 
of cognition: visuospatial and executive functioning, naming, memory (i.e. delayed recall), 
attention, language, abstraction, and orientation (Nasreddine et al., 2005) (see Appendix C). The 
MoCA is designed to provide a measure of global cognitive function. Scores ≥ 26 indicate 
normal cognition, scores 19-25 indicate MCI, and scores less than 19 indicate dementia (Freitas, 
Simoes, Alves, & Santana, 2013). Using these cut-off scores, the MoCA has 90% and 100% 
specificity to detect MCI and mild AD, respectively, as well as a sensitivity of 87% (Nasreddine 
et al., 2005). 
 2.2.2.2. Overnight Procedural Memory Consolidation Task. Since sleep quality 
impacts overnight memory consolidation, an overnight memory consolidation task was 
developed for use in this study and mimics the procedural protocol of Walker and Stickgold 
(2004). This task was developed as an application for an Android tablet. This task consists of 4 
circles, labeled 1, 2, 3, and 4. Once the task starts, a participant is presented with a 5 number 
sequence consisting of numbers 1-4 which remains on the screen. The participant was told to 
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remember this sequence and asked to tap the sequence “as quickly and as accurately as possible” 
for 30 seconds followed by a 30 second rest period. This protocol was repeated for 12 trials with 
the same sequence. Participants were instructed to complete this task once in the evening on the 
first visit (following a full completion of the protocol with the research team as training) and 
once the next morning after awakening. A variety of information was taken from this task 
including number of correct sequences, % improvement overnight, speed of tapping, etc. (Table 
1). It is shown in previous literature that procedural memory should improve by ~20% in 
individuals with proper sleep efficiency (Walker, Brakefield, Morgan, Hobson, & Stickgold, 
2002; Stickgold & Walker, 2005). 
Table 1 
Overnight Memory Consolidation Variables 
Variable Name Definition 
Total Taps Total sum of taps for the 12 trial assessment 
Total Correct Taps Total sum of correct taps for the 12 trial 
assessment 
Total Correct Sequences Total sum of correct sequences for the 12 
trial assessment 
Average Correct Taps per Trial The number of correct taps divided by 
number of trials (12) 
Efficiency Number of correct sequences divided by 
number of trials (12) 
Average Speed (Number of taps per trial) How fast a 
participant is tapping 
Percent Correct Taps Percentage of total correct taps 
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Table 1 Continued 
 
 
Percent Improvement Percentage improvement of correct taps 
between night and morning assessments 
Difference in Total Number of Taps between 
Night and Morning 
Difference between morning and night of 
total taps 
Difference in Total Correct Taps between 
Night and Morning 
Difference between morning and night of 
correct taps 
Difference in Number of Correct Sequences 
between Night and Morning 
Difference between morning and night of 
correct sequences 
Average Error Rate per Trial Number of incorrect taps divided by number 
of trials (12) 
Average Number of Taps for Last 3 Trials 
(Morning and Night) 
Average number of total taps for the last 3 
trials for both morning and night assessments 
Average Correct Sequences for Last 3 Trials 
(Morning and Night) 
Average number of correct sequences for the 
last 3 trials for both morning and night 
assessments 
Difference in Number of Taps in Last 3 
Trials between Night and Morning 
Difference between morning and night of 
total taps in the last 3 trials 
Difference in Number of Correct Sequences 
in Last 3 Trials between Night and Morning 
Difference between morning and night of 
correct sequences in last 3 trials 
Percent Difference in Number of Taps (Last 
3 Trials) 
Percentage of difference between morning 
and night of total taps for the last 3 trials 
Percent Difference in Number of Correct 
Sequences (Last 3 Trials) 
Percentage of difference between morning 
and night of correct sequences for the last 3 
trials 
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Table 1 Continued  
Average Number of Taps for Last 6 Trials 
(Morning and Night) 
Average Number of Total Taps for the Last 6 
Trials for both morning and night 
assessments 
Average Correct Sequences for Last 6 Trials 
(Morning and Night) 
Average number of correct sequences for the 
last 6 trials for both morning and night 
assessments 
Difference in Number of Taps in Last 6 
Trials between Night and Morning 
Difference between morning and night of 
total taps in the last 6 trials 
Difference in Number of Correct Sequences 
in Last 6 Trials between Night and Morning 
Difference between morning and night of 
correct sequences in last 6 trials 
Percent Difference in Number of Taps (Last 
6 Trials) 
Percentage of difference between morning 
and night of total taps for the last 6 trials 
Percent Difference in Number of Correct 
Sequences (Last 6 Trials) 
Difference between morning and night of 
correct sequences in last 6 trials 
Note. All output variables assess overnight memory consolidation using a sequence tapping 
application adapted from Walker and Stickgold literature. 
2.2.2.3. Trail Making Test Parts A and B. The Trail Making Test (TMT) is comprised 
of two parts; Trails A and Trails B (see Appendix D). Both parts consist of 25 circles scattered 
across a page. For Trails A, participants were instructed to keep their pen on the paper while 
connecting circles containing numbers 1-25 in ascending order (e.g. 1 → 2 → 3 → 4 …). For 
Trails B, the circles contain both numbers (1-13) and letters (A-L) and participants have the 
added task of connecting the circles alternating between numbers and letters in ascending order 
(e.g. 1 → A → 2 → B …) (Tombaugh, 2004). Shorter sample versions of Trails A and Trails B 
were given before each assessment to ensure participants understand the instructions. If an error 
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was made by a participant during the assessment, researchers immediately corrected the mistake 
before allowing the assessment to continue. Both assessments were timed by researchers. The 
TMT assesses visual scanning, sequencing, and task switching abilities which primarily activates 
the prefrontal regions of the frontal lobe (Ashendorf et al., 2008; Salthouse, 2011). TMT shows 
good psychometric properties, including construct validity and test-retest reliability (Giovagnoli 
et al., 1996; Amodio et al., 2002). 
 2.2.2.4. Hopkins Verbal Learning Test-Revised. Form 1 of the Hopkins Verbal 
Learning Test-Revised (HVLT-R) was used for all participants (Benedict, Schretlen, Groninger, 
& Brandt, 1998). This assessment involves 12 target words, four words from each of three 
semantic categories, to be learned over the course of three learning trials. After a 20-25 minute 
delay, a delayed free recall trial and recognition trial was administered. The delayed free recall 
trial allowed the participant to list all words from the original list that they remember. The 
recognition trial allowed participants to indicate whether each word on a list of 24 words was or 
was not on the original list. This list of words contains the 12 target words, as well as six 
semantically related and six semantically unrelated words that were not on the original list. This 
assessment is used to measure verbal learning, episodic verbal memory, and confrontational 
word retrieval through activation of the hippocampal region, temporal lobe, and subsequent 
connections to the cortex (Xu, Xiao, Rahardjo, & Hogervorst, 2015). The HVLT-R has 
acceptable reliability and good validity, and is best suited for use in an elderly population with 
suspected dementia (Benedict, Schretlen, Groninger, & Brandt, 1998; Sharpito, Benedict, 
Schretlen, & Brandt, 1999). 
 2.2.2.5. Boston Naming Test. The Boston Naming Test (BNT) short form contains 15 
images of different objects (e.g. hammock, Sphinx, etc.) of varied difficulty (Mack, Freed, 
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Williams, & Henderson, 1992). Participants were asked to identify the object in the picture as 
quickly as possible. If a participant could not identify the object within 10 seconds or gave an 
incorrect response, he or she was given a semantic cue. If the participant was still unable to 
identify the object, he or she was given a phonemic cue (e.g. the first letter of the object). If the 
participant was again not able to identify the object, researchers provided the object name as a 
multiple choice option among four words. The BNT assesses confrontational word retrieval and 
semantic memory focused in the posterior section of the left temporal lobe (Trebuchon-Da 
Fonseca et al, 2009). The BNT short form showed good psychometric properties (Fastenau, 
Denburg, & Mauer, 1998). 
 2.2.2.6. Brief Visuospatial Memory Test-Revised. The Brief Visuospatial Memory 
Test-Revised (BVMT-R) Form 1 was used on all participants (Benedict, Schretlen, Groninger, 
Dobraski, & Schpritz, 1996). For this assessment, participants were instructed to study an array 
of 6 simple, 2-dimensional figures for 10 seconds and draw as many figures as they can 
remember in the proper places after the display is removed from sight. There are three trials of 
drawing, followed by a delayed recall trial 25 minutes after the last sighting of the display. 
Additionally, there is a recognition trial in which researchers showed a series of figures one at a 
time and participants were asked to identify whether each figure was or was not on the original 
display. This test assesses visual learning and memory, focused in the visual cortex of the 
occipital lobe (Tam & Schmitter-Edgecombe, 2013). The BVMT-R shows excellent interform 
reliability and construct and criterion validity (Benedict, Schretlen, Groninger, Dobraski, & 
Schpritz, 1996). 
2.2.3. Cognitive Reserve Measures. Proxy measures of cognitive reserve such as 
intelligence, reading ability, and vocabulary were assessed in order to quantify if a participant 
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had low or high levels of cognitive reserve. Aging research has shown that premorbid 
intelligence, as assessed with word-reading tests, can help determine cognitive reserve capacity 
when combined with assessing vocabulary since these measures of cognition tend to remain 
stable over time (Stern, 2009). Cognitive reserve proxy measures were only administered to 
Study 2 participants. 
2.2.3.1. American National Adult Reading Test. The American National Adult 
Reading Test (AMNART) is a neuropsychological assessment used to provide a measure of 
premorbid intelligence before onset of illness or injury (Blair & Spreen, 1989; Uttl, 2002). 
Participants were presented with 45 irregularly spelled words one at a time and prompted for a 
single pronunciation of each word (see Appendix E).  
2.2.3.2. Vocabulary subtest of the Wechsler Adult Intelligence Scale-Third Edition. 
The vocabulary subtest of the Wechsler Adult Intelligence Scale-Third Edition (WAIS-III) is a 
component of an in-depth adult intelligence scale that measures semantic knowledge. 
Participants were asked to define words presented to them (Tulsky, Saklofske, Wilkins, & Weiss, 
2001). 
2.2.4. Sleep Measures. The purpose of completing various sleep measures was to get a 
more comprehensive understanding of a participant’s sleep patterns and to compare sleep quality 
to depression and neurocognitive status. Objective (SleepMove, Actiwatch) and self-report 
(PSQI, Stanford Sleepiness Scale, Consensus Sleep Diary, and Epworth Sleepiness Scale) 
indices were used to identify sleep fragmentation by measuring sleep quality, as well as sleep 
deprivation through daytime sleepiness.  SleepMove device measures were not analyzed as part 
of this thesis and are only included here to identify it as part of the protocol for the study. Sleep 
measures were a main component of both Study 1 and Study 2. 
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2.2.4.1. SleepMove. The SleepMove system is a patented (US Patent 13/106,451) 
mattress device developed by our team at Activas Diagnostics (Activas-Diagnostics.com). The 
novel sleep monitoring device consists of 32 small pressure sensors embedded into a noninvasive 
sheet and used to collect data on movement and respiration throughout the night. 16 are 50-
pound sensors located at the head and torso areas. The remaining 16 sensors are 1-pound sensors 
located at the chest, abdomen, and pelvis regions. With algorithms developed by our team, the 
SleepMove device is designed to identify movement and sleep-wake parameters, as well as 
respiration throughout the night. Using a noninvasive design, a waterproof-type sheet with 
embedded flat sensors is placed directly under a standard bed sheet with the goal of becoming an 
alternative to current sleep monitoring techniques. 
2.2.4.2. Philips Respironics ActiwatchTM The Actiwatch 2 is a small (43mm x 23mm x 
10mm, 16g), waterproof, unobtrusive device worn on a participant’s wrist and used to measure 
overnight movement and sleep/wake parameters with accelerometer-type sensors (Philips 
Respironics, 2013). This device is worn on the non-dominant wrist of the participant for 7 
consecutive days and nights as a standard measure of sleep/wake. The device has been shown to 
be sufficient in assessing movement in older adults through empirical research (Hurelbrink, 
Lewis, & Barker, 2005). In addition, it is the gold standard for assessing sleep parameters (for 
output measures see Table 2). 
Table 2 
Philips Respironics Actigraphic Output Measures 
Output Variable Definition of Output Variable 
Bed Time Time participant got into bed for the night 
(24 hour clock) 
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Table 2 Continued  
Get Up Time Time participant got out of bed after sleep 
period (24 hour clock) 
Time in Bed Difference between “Bed Time” and “Get 
Up Time” (hr:min) 
Sleep Start Time participant fell asleep (24 hour clock) 
Sleep End Time participant had their final awakening 
(24 hour clock) 
Assumed Sleep Time between “Sleep Start” and “Sleep End” 
(hr:min) 
Actual Sleep Time Amount of sleep determined by the 
Actiwatch algorithm (Assumed Sleep – 
Wake time) (hr:min) 
Actual Sleep (%) Percentage of actual sleep throughout the 
night 
Actual Wake Time Amount of time awake determined by the 
Actiwatch algorithm (hr:min) 
Actual Wake (%) Percentage of time spent awake throughout 
the night 
Sleep Efficiency “Actual Sleep Time” / “Time in Bed (%) 
Sleep Latency Latency before sleep onset following bed 
time (hr:min) 
Sleep Bouts The actual number of episodes of sleep 
Wake Bouts The actual number of episodes of 
wakefulness 
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Table 2 Continued  
Mean Sleep Bout Time Total duration of sleep / sleep bouts (hr:min) 
Mean Wake Bout Time Total duration of sleep / wake bouts (hr:min) 
Immobile Mins Total number of minutes during “Assumed 
Sleep” where the counts per minute are 
below a predetermined “immobility” 
threshold 
Immobile Time (%) “Immobile Mins” / “Assumed Sleep” (%) 
Moving Mins Total number of minutes during “Assumed 
Sleep” where the counts per minute are 
above a predetermined “immobility” 
threshold 
Moving Time (%) “Moving Mins” / “Assumed Sleep” (%) 
No of Immobile Phases The number continuous periods made up of 
consecutive epochs where the counts are < 
than the “immobility” threshold. E.g. 
suppose a score of <4 was recorded in 4 
consecutive epochs. This is classified as one 
Immobile Phase. 
Mean Length Immobility Average length of the immobile bouts 
One Minute Immobility The number of immobile phases where the 
duration is no more than 1 minute. 
One Min Immobility (%) The number of immobile phases of 1 minute 
as a proportion of the number of immobile 
phases (%). 
Fragmentation Index The addition of Percentage Minutes Moving 
and Percentage Immobility. This is used as 
an indicator of restlessness. 
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Table 2 Continued  
Avg. Wake Movement Average activity score per epoch of the wake 
period before the previous night’s sleep. 
Calculated by activity counts between sleep 
end in the morning and sleep start at night. 
 Note. All output variables from participant Actiwatch data, obtained using Philips Actiware 6, 
version 6.0.9. 
 
 2.2.4.3. Pittsburgh Sleep Quality Index. The Pittsburgh Sleep Quality Index (PSQI; 
Buysse, Reynolds, Monk, Berman, & Kupfer, 1989) is a self-report measure that assesses sleep 
quality over a one-month time interval. Sleep quality is determined through assessment of seven 
components of sleep: subjective sleep quality, sleep latency, sleep duration, habitual sleep 
efficiency, sleep disturbances, use of sleeping medications, and daytime functioning (see 
Appendix F) 
 2.2.4.4. Stanford Sleepiness Scale. The Stanford Sleepiness Scale (SSS; Hoddes, 
Zarcone, Smythe, Phillips, & Dement, 1973) is a self-report measure of alertness for each hour 
throughout the day, over a period of 7 consecutive days (see Appendix G). This subjective 
measure is scored using a 7-point scale to indicate degree of sleepiness (e.g. 1= feeling active, 
vital, alert, or wide awake; 2= functioning at high levels but not fully alert, etc.; and X = asleep). 
This measure allows for self-report parameters of sleep deprivation. Participants completed this 
scale starting on the first day of the sleep study and continuing for the 7 days they wore the 
Actiwatch (above; 2.2.4.2.). 
 2.2.4.5. Consensus Sleep Diary. Participants were asked to complete a standardized 
sleep diary (see Appendix H) for seven consecutive days while wearing the Actiwatch (above; 
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2.2.4.2.). The Consensus Sleep Diary is a validated subjective measure used to assess parameters 
of sleep quality such as sleep/wake times, self-reported sleep fragmentation, sleep quality, nap 
measures, etc. (Carney et al., 2012). 
 2.2.4.6. Epworth Sleepiness Scale. The Epworth Sleepiness Scale (ESS; Johns, 1992) is 
a self-report measure of dozing likelihood in various situations throughout the day. The 
participant rated his or her probability of falling asleep on a scale from 0 (no chance of dozing) 
to 3 (high chance of dozing) for eight different situations that most people engage in during their 
daily life (e.g. watching TV, sitting as a passenger in a car for an hour without a break, etc.) (see 
Appendix I). Responses were used to analyze overall daytime sleepiness and to assess sleep 
deprivation. 
2.3. Study Design and Procedure. 
 Participants from either the MCI group or the group of undiagnosed community controls 
who endorsed current depression in intake interview were considered positive for current 
depression (G1, Current Dep). Group 1 includes participants from Study 1 and Study 2. 
Participants from either the MCI group or the group of undiagnosed community controls who 
endorsed a history of diagnosed depression but no current depression were considered positive 
for history of diagnosed depression (G2, History of Dep). Group 2 includes participants from 
Study 2 only. Those who did not endorse current depression or history of diagnosed depression 
were considered negative for depression (G3, Non-Dep). Group 3 includes participants from 
Study 2 only, as we do not have information on history of diagnosed depression from 
participants in Study 1 that did not endorse current depression. 
2.3.1 Participant Recruitment Protocol. Participants with previous diagnosis of MCI 
were screened by clinical staff at the Mood and Memory Clinic at Northern Light Acadia 
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Hospital for study eligibility based on inclusionary and exclusionary criteria, and then referred to 
the study staff for scheduling. Undiagnosed comparison participants were a community sample 
who contacted research assistants via phone or email. Those who expressed interest in the study 
were screened for eligibility using a recruitment script for the study, based on inclusionary and 
exclusionary criteria, by research assistants over the phone. The University of Maine Center on 
Aging also provided access to their large database of names and contact information of local 
older adults interested in participating in research studies. Appropriately aged individuals located 
in the Greater Bangor area from this database were contacted by a research assistant over the 
phone to determine interest and eligibility using a recruitment script for the study based on 
inclusionary and exclusionary criteria. 
2.3.2. Sleep Study Visit. Once individuals met eligibility criteria and agreed to 
participate in the study over the phone, a study visit was scheduled to complete informed consent 
and set up the 2 night sleep study at the participant’s home. The study visit was conducted at the 




Figure 1. Study Protocol Timeline. A timeline of the participant experience in this study. 
Participants were recruited from Northern Light Acadia Hospital or community areas and 
completed a sleep study visit and a follow-up neurocognitive visit.  
 2.3.2.1. Informed Consent. Upon arrival to each participant’s home, the trained 
undergraduate or graduate research assistant explained the study and reviewed all aspects of the 
informed consent with the participant. Participants were encouraged to ask questions or for 
additional information at any time. After participants signed the informed consent, they were 
given their own copy of the informed consent to keep for their records. 
 2.3.2.2. MoCA Administration. Following review and signing of informed consent, the 
MoCA (Appendix C) was administered by a trained research assistant, following protocol 
according to Nasreddine (2005) that included standardized scripts for proper administration.  
 2.3.2.3. Demographics. Questions regarding participant demographic information and 
health history were delivered orally and recorded by a trained research assistant (see Appendix 
J). Demographic questions were split into three categories: 1.) patient characteristics (i.e. age, 
dominant hand, marital status, living situation), 2.) medical history (i.e. cardiovascular disease, 
cerebrovascular disease, diabetes, traumatic brain injury, etc.), and 3.) substance use (current and 
historical). Everything a participant answered to the questions were written down. It should be 
noted that, in Study 1, demographic questions were compiled by patients’ self-report through a 
questionnaire on a tablet. We moved towards collecting demographic questions orally to ensure 
that all questions were answered and that participants fully understood what they were being 
asked. 
2.3.2.4. Depression Measures. The research assistant explained and orally delivered all 
depression measures in Study 2. Participants were instructed on how to respond to the 
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supplemental questions (Appendix B) and the CES-D (Appendix A). For the supplemental 
questions, the research assistant recorded all responses given by the participant. The participant 
was seated next to the research assistant and was able to look at the CES-D in order to reference 
the ranking scale for each response. The research assistant recorded all responses for this 
measure as well.  
2.3.2.5. Sleep Measures. The graduate or undergraduate research assistant verbally gave 
directions on how to fill out the Epworth Sleepiness Scale (Appendix I) and the PSQI (Appendix 
F) and recorded all responses. If participants requested, research assistants would further explain 
questions. Research assistants then explained how to complete the SSS (Appendix G). 
Participants were instructed to place a scale rating for the degree of sleepiness they were feeling 
for each hour of the day. Participants completed all hours until the current moment for the 
present day and research assistants answered any questions. In addition, research assistants 
explained how to complete the Consensus Sleep Diary (Appendix H), and read an explained 
questions as necessary. Participants were asked to complete both the SSS and the Consensus 
Sleep Diary for 7 consecutive days. Finally, research assistants explained the use of the 
Actiwatch and placed it on the non-dominant wrist of the participant. Participants were instructed 
to leave the watch on 24 hours a day for 7 days, with the exception of being in water (e.g. 
swimming, bathing, washing dishes). Participants were additionally instructed to press and hold 
the event marker button on the side of the Actiwatch for 3 seconds when they felt sleep onset 
was coming soon at night. Upon completion of these assessments and Actiwatch placement, 
research assistants scheduled a time to return to the participant’s home in 7 days for <10 minutes 
to retrieve the Actiwatch, Consensus Sleep Diary, and SSS. Eventually, the study team began 
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utilizing UPS for these pick-ups by giving participants an envelope with shipping label and 
setting up a pickup time for these materials after 7 days of use. 
2.3.2.6. SleepMove Placement. Following completion of paperwork, participants were 
asked to show research assistants to their bedroom and to instruct research assistants where they 
normally lay on their bed on a typical night. The bed was stripped of all bed sheets and blankets 
and research assistants placed a new, clinical fitted sheet on top of the participant’s mattress. 
Then, research assistants place the sensor sheet on top of the clinical fitted sheet. After placing 
the sensor sheet, research assistants ensured that the end with three sensors is located at the 
head/top and the end with two sensors is located at the feet/bottom of the mattress. Research 
assistants also ensured that all sensors are flat with the small circular sensor on top of the large 
square sensor and that wires were as flat as possible underneath the sensor pad and traveling out 
from the sides of the mattress (two connectors per side). Research assistants then ran the 
connector ribbon cables along the side of the mattress to the foot of the bed and place the second 
clinical fitted sheet on top of the sensor pad. Research assistants ensured wires were not a fall 
hazard and that no sensors were bent or sticking up.  
In order to start recording data, research assistants plugged connector ribbon cables into 
the wireless transmitting device (cable “A” attaches to input “A”, cable “B” attaches to input 
“B”, etc.). A tool was used to press the “Start” button on the box to begin mattress recording. 
Research assistants looked in the hole on the opposite side of the “Start” button to ensure the 
LED is flashing and thus the mattress device had begun recording. Research assistants tucked the 
box and cables underneath the participant’s bed so that no materials were exposed and finally, 
remade the participant’s bed with the participant’s blankets and pillows.  
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2.3.2.7. Overnight Memory Consolidation Task Training. Participants were given the 
opportunity to complete the overnight memory consolidation task in full as training. Research 
assistants gave participants a printed copy of instructions explaining the use of the tablet 
beginning at “turning on the tablet” and going through which application to click on and how to 
begin the task. Research assistants then ran through the task protocol completing the steps for 1 
trial before handing the tablet to the participant to complete the remaining 11 trials. Participants 
were encouraged to ask questions and research assistants looked on to the training to ensure 
participants understood the task. Research assistants reminded the participants that they need to 
tap the sequence as many times and as accurately as possible in each 30 second test phase using 
their non-dominant hand. Following completion of the training and after a brief break if needed, 
participants were asked to complete “Night 1” of the procedural memory task. Research 
assistants were still present when the participant completed this task but they did not prompt or 
correct how the participant was performing. After the participant completed the full 12 trials of 
this task, they were asked what time would be best for a research assistant to call in the morning 
to remind them to complete their morning 12 trials. The sheet with tablet instructions was left 
with the participant and they were told to call if there were any questions or concerns regarding 
the task. Participants were further asked not to touch the tablet following completion of the task 
in the morning and that research assistants would pick up the tablet in 2 days. It should be noted 
that participants in Study 1 completed ONMC task on night 2 and the morning following night 2. 
ONMC task completion was moved to night 1 and the morning following night 1 so testing could 
be completed as close to training as possible, which was especially important for MCI 
participants. The task and output measures were identical between Study 1 and Study 2. A 
procedural memory consolidation task protocol is explained in Figure 2. 
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Figure 2. Overnight Memory Consolidation Task Protocol. The overnight memory 
consolidation task is displayed above. A view of the testing screen is shown in the top left 
corner, in which participants were asked to tap the red circles in the order of the sequence 
provided. 
 
2.3.3. Neurocognitive Assessment Visit. Participants were contacted via phone to 
schedule a follow-up neurocognitive assessment for approximately one month following 
completion of the sleep study. Upon arrival to the participant’s home at the scheduled time, 
research assistants reminded participants that the study is both voluntary and confidential. 
Participants were also reminded what they were to be completing at the visit and about the risks 
and benefits of participation. To begin the neurocognitive assessment, the graduate research 
assistant presented participants with scripted directions and an orally delivered word list to 
complete the direct recall portion of the HVLT-R. Then, the graduate research assistant followed 
scripted directions for the TMT. Participants completed Trail Making Test Part A and Trail 
Making Test Part B (Appendix D). An undergraduate research assistant timed the Trails A 
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assessment and the Trails B assessment and recorded the time upon completion. After 
completion of the TMT, the graduate research assistant gave instructions for completion of the 
BNT while an undergraduate research assistant recorded responses. Participants were then given 
directions for the BVMT-R and completed the direct recall portion of this assessment. The TMT, 
BNT, and direct recall portion of the BVMT-R were used as the delay time for the HVLT-R as 
these assessments together last about 10-20 minutes. If additional delay time was needed, the 
graduate research assistant gave the participant a break from testing. Following completion of 
these tasks/break, participants were asked to recall the word list from the HVLT-R and to 
complete a recognition memory task. Upon completion of the HVLT-R, the graduate research 
assistant then presented participants with scripted directions and a paper word list to complete 
the AMNART (see Appendix E). Each word was individually shown to the participant and, after 
the participant provided a single pronunciation of the word, the research assistant instructed the 
participant to move on to the next word after about a one second delay. Then, the vocabulary 
subtest of the WAIS-III was administered by a trained graduate research assistant, following 
standardized scripts for proper administration. The AMNART and WAIS-III Vocabulary subtest 
served as the delay for the BVMT-R, as they together took approximately 25 minutes. Following 
completion of these tasks, participants were asked to draw what they could remember from the 
display given earlier on the BVMT-R, and complete a recognition memory task. Throughout the 
assessment, that lasted no longer than 90 minutes, participants were encouraged to take breaks as 
needed, and were reminded that they were entitled to discontinue at any point without loss of 
compensation. 
 2.3.4. Scoring Protocol. All packets were scored by the graduate research assistant or 
scored by a trained undergraduate research assistant and double scored by the graduate research 
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assistant to ensure accurate scores were reported. All standardized assessments conducted were 
scored according to original protocol. All original files were de-identified and stored in a double-
locked cabinet in a separate lab room. 
 2.3.4.1. Philips Respironics Actiwatch Data Processing. Data from the Philips 
Respironics Actiwatch, “Actiwatch 2” were collected for a total of 7 consecutive days and 
nights. Data were processed using Version 6.0.9 of “Philips Actiware 6” software developed by 
Philips Respironics. Actiwatch 2 devices were placed on the Actiwatch 2 Communications Dock 
(SN:A2D10139) and processed using a Windows 10 Home, 64-bit, version 1809 computer. 
Philips Actiware 2 allowed various output parameters for sleep wake and sleep movement (table 
2) to be used for analysis. 
 2.3.4.2. Memory Consolidation Application Data Processing. The software for this 
protocol was developed for our sleep study and adapted from the work of Stickgold and 
colleagues (Walker, Brakefield, Morgan, Hobson, & Stickgold, 2002; Walker & Stickgold, 
2004). Data from the memory application were downloaded in command prompt (cmd). Data 
collected included: dates and times of completion for the memory consolidation task in the 
evening and morning, sequence given, correct sequences tapped, and number of total taps. From 
this data, a separate coded excel file was used to calculate output variables of interest (see table 
2). 
2.4. Data Analysis 
 2.4.1. Statistical Analysis. Data were analyzed using IBM Statistical Package for the 
Social Sciences - Version 26 (IBM-SPSS-26) for OS-X. Demographic and reported health 
history characteristics were analyzed for group differences between currently depressed (n=9), 
history of diagnosed depression (n=7), and non-depressed from study 2 (n=22) groups using one-
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way ANOVA for continuous variables, and Kruskal-Wallis Test for categorical variables. 
Overnight procedural memory consolidation speed and percent improvement were calculated and 
analyzed using parametric tests. Composite scores for neurocognitive assessments and subjective 
sleep measures were calculated according to protocol. Parametric variables were analyzed using 
General Linear Modeling (GLM) and regression analyses while nonparametric variables were 
analyzed using Kruskal Wallis and other methods. 
 For CURRENT DEPRESSION, separate multivariate GLMs with current depression 
status (binary: yes/no) as a factor and covariate MCI status (clinically diagnosed positive or 
negative) was examined. Categories of dependent variables were examined separately and 
dependent variables included 1.) self-report sleep measures (SSS, ESS, PSQI), 2.) wrist 
actigraphy, 3.) overnight memory consolidation task variables, 4.) 30-day neurocognitive follow-
up measures, and 5.) cognitive reserve measures (WAIS-III Vocabulary Subtest, AMNART).  
These analyses used groups current depression vs. no current depression. 
Current depression group (n=9) included participants who answered “yes” for current 
depression from study 1 (query: yes/no choice; n=6) and participants who answered “yes” for 
current depression from study 2 (query: yes/no choice for current; n=3). No current depression 
group (n=41) included participants that answered “no” for current depression from study 2 
(n=22). For exploratory analyses for no current depression, I also examined those with a positive 
history of diagnosed depression but no current depression from study 2 (n=7) as well as those 
that answered “no” for current depression from study 1 (n=12).  
For CURRENT DEPRESSION, multivariate GLM with current depression status (binary: 
yes/no) as a factor and covariate MCI status (clinically diagnosed positive or negative) was 
examined. Categories of dependent variables were examined separately and included 1.) self-
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report sleep measures (SSS, ESS, PSQI), 2.) wrist actigraphy, 3.) overnight memory 
consolidation task variables, 4.) 30-day neurocognitive follow-up measures, and 5.) cognitive 
reserve measures (WAIS-III Vocabulary Subtest, AMNART). These analyses used groups 
current depression vs. no depression. 
In the next analysis, I was able to analyze current depression group (n=9) excluding those 
with a history of depression (n=7, Study 2). Please recall that in Study 1, history of depression 
was not queried.  No depression group (n=22) included participants that answered “no” for 
current depression from study 2.  
For HISTORICAL DEPRESSION, multivariate GLMs with history of diagnosed 
depression status (binary: yes/no) as a factor and covariate MCI status (clinically diagnosed 
positive or negative) was examined. Categories of dependent variables were examined separately 
and dependent variables included 1.) self-report sleep measures (SSS, ESS, PSQI), 2.) wrist 
actigraphy, 3.) overnight memory consolidation task variables, 4.) 30-day neurocognitive follow-
up measures, and 5.) cognitive reserve measures (WAIS-III Vocabulary Subtest, AMNART). 
History of diagnosed depression group includes participants that answered “yes” for 
history of diagnosed depression from study 2 (query: yes/no choice for history; n=9). No 
depression group includes participants that answered “no” for history of diagnosed depression 
from study 2 (n=22). One participant endorsed current depression but did not report a history of 
diagnosed depression and was excluded from analyses. 
 For ANY DEPRESSION, multivariate GLMs with current and/or historical depression 
status (binary: yes/no for history and current) as a factor and covariate MCI status (clinically 
diagnosed positive or negative) was examined. Categories of dependent variables were run 
separately and dependent variables included 1.) self-report sleep measures (SSS, ESS, PSQI), 2.) 
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wrist actigraphy, 3.) overnight memory consolidation task variables, 4.) 30-day neurocognitive 
follow-up measures, and 5.) cognitive reserve measures (WAIS-III Vocabulary Subtest, 
AMNART). 
Any depression group includes: participants that answered “yes” for current depression 
from study 1 (query: yes/no choice; n=6), participants that answered “yes” for current depression 
from study 2 (query: yes/no choice for current; n=3), and participants that answered “yes” for 
history of diagnosed depression from study 2 (query: yes/no choice for history; n=7). No 
depression group includes participants that answered “no” for current depression from study 2 
(n=22). This group EXCLUDED participants that indicated no current depression in study 1 
(n=12) due to lack of information on history of diagnosed depression. 
 Simple linear regression was run to assess variables that impacted CES-D total scores in 
Study 2. In one model, MCI status (clinically diagnosed positive or negative), Stanford 
Sleepiness Scale (SSS) average score, and PSQI Component 7: daytime dysfunction are factors. A 
second model assesses MCI status (clinically diagnosed positive or negative) and self-reported 
sleep quality and uses MCI status (clinically diagnosed positive or negative) and PSQI composite 
score as factors. A third model assesses cognition and uses MCI status (clinically diagnosed 
positive or negative), BVMT-R total recall raw score, and BVMT-R percent retained from final 
learning trial to delayed recall as factors. The dependent variable for all models is CES-D total 
score for participants in Study 2. Possible factors that influenced CES-D total score were found 
through exploratory statistics. 
 Regression analysis was used to investigate whether MCI status based on MoCA score 
mediates the effect of current depression status on mean sleep efficiency. A second regression 
analysis was conducted to assess whether MCI status based on MoCA score mediates the effect 
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of current depression status on MoCA attention scores. Mediational models were built based on 
regression results. For all regression analyses, current depression and no depression groups were 
assessed. Current depression group includes participants who answered “yes” for current 
depression from study 1 (query: yes/no choice; n=6) and participants who answered “yes” for 
current depression from study 2 (query: yes/no choice for current; n=3). No depression group 
includes participants that answered “no” for current depression from study 2 (n=22). This group 
EXCLUDED participants that have a history of diagnosed depression but no current depression 
(n=7 for study 2) and participants that indicated no current depression in study 1 (n=12) due to 
lack of information on history of diagnosed depression. Significance for indirect effects (a*b) in 
mediational models was tested using a percentile bootstrap estimation approach with 1000 
samples. 
 Sample size constrained model building. Because a general linear model was applied 
with group as the between subjects factor, MCI status, which was significantly different between 
groups, was used as a covariate in the analyses. Main effects were calculated with 95% 
confidence intervals and were adjusted to LSD at a 5% significance level. Levene’s test was used 











3.1. Demographic Characteristics. 
 Hypothesis I proposed that groups with current and/or history of diagnosed depression 
would show more chronic health conditions than the non-depressed comparison group. Thirty 
eight recruited participants were included in demographic analyses, resulting in current 
depression (DepCur) group from study 1 and study 2 (n=9), history of diagnosed depression but 
no current depression (DepHx) group from study 2 (n=7), and a sociodemographically similar 
group without current or historical depression from study 2 (Control 2; n=22). Participants from 
study 1 who endorsed no current depression (n=12) were excluded from demographic analyses 
due to lack of information on historical depression status. 
Table 3 
Participant Demographics and Health Characteristics 
Variable (m±SD or 
% (n)) 



















  n.s. 






  n.s. 
MCI No 91% (20) 100% 
(7) 
33% (3) 79% 
(30) 
0.001 
  Yes 9% (2) 0% (0) 67% (6) 21% (8)   
Sex Male 18% (4) 43% (3) 33% (3) 26% 
(10) 
n.s. 




Table 3 Continued       
Marital Status Never 
Married 
9% (2) 0% (0) 22% (2) 11% (4) n.s. 
  Divorced 41% (9) 0% (0) 11% (1) 26% 
(10) 
  
  Widowed 14% (3) 14% (1) 0% (0) 11% (4)   
  Has a partner 
but not 
married 
0% (0) 14% (1) 0% (0) 3% (1)   
  Married 36% (8) 72% (5) 67% (6) 50% 
(19) 
  
Living Situation Lives alone 64% (14) 14% (1) 33% (3) 47% 
(18) 
0.026 




36% (8) 86% (6) 67% (6) 53% 
(20) 
  






0% (0) 0% (0) 11% (1) 3% (1) n.s. 




0% (0) 0% (0) 0% (0) 0% (0)   




5% (1) 0% (0) 11% (1) 5% (2)   
  Completed 
high school 
(grades 9-12) 
18% (4) 29% (2) 11% (1) 18% (7)   
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32% (7) 29% (2) 11% (1) 26% 
(10) 
  




23% (5) 0% (0) 33% (3) 21% (8)   





14% (3) 43% (3) 11% (1) 18% (7)   
  Doctoral 
degree (PhD, 
medicine) 
9% (2) 0% (0) 11% (1) 8% (3)   
OSA No 91% (20) 57% (4) 89% (8) 84% 
(32) 
n.s. 
  Yes 9% (2) 43% (3) 11% (1) 16% (6)   
Cerebrovascular 
Disease 
No 95% (21) 71% (5) 78% (7) 87% 
(33) 
n.s. 
  Yes 5% (1) 29% (2) 22% (2) 13% (5)   
Other Psychiatric 
Disorders 
No 86% (19) 71% (5) 78% (7) 82% 
(31) 
n.s. 
  Yes 14% (3) 29% (2) 22% (2) 18% (7)   




Table 3 Continued       
  Less than 
once a month 
0% (0) 0% (0) 22% (2) 5% (2)   
  About once a 
month 
23% (5) 29% (2) 11% (1) 21% (8)   
  About once a 
week 
23% (5) 29% (2) 0% (0) 18% (7)   
  A few times 
a week 
18% (4) 29% (2) 22% (2) 21% (8)   
  Daily or 
almost daily 
14% (3) 0% (0) 0% (0) 8% (3)   
Note. Results reveal that participants were matched on demographics and health variables in the 
three groups with the exception of MCI status (χ2=14.62, p = 0.001) and living situation 
(χ2=7.28, p = 0.026). Additional demographic variables that were found to be not significant 
across groups: dominant hand, cardiovascular disease, arthritis, diabetes, heart attack/cardiac 
arrest, body mass index, traumatic brain injury, hypercholesterolemia, hypertension, thyroid 
disease, and current smoking status. 
 
 Table 3 shows group differences in demographic and health variables assessed using a 
parametric measure (one-way ANOVA) for continuous variables, and a non-parametric measure 
(Kruskal Wallis Test) for categorical variables. Demographic variables including age, sex, race, 
marital status, living situation, education level, body mass index (BMI), and dominant hand were 
collected. Living situation was the only demographic variable that was significantly different 
between DepCur, DepHx, and Control 2 groups (χ2=7.28, p = 0.026). All other demographics 
were not significant. Health variables were also collected to ensure groups were well matched. 
Health characteristics collected include presence or absence of the following: mild cognitive 
impairment (MCI), obstructive sleep apnea (OSA), arthritis, cardiovascular disease, smoking, 
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alcohol use, diabetes, heart attack or cardiac arrest, traumatic brain injury (TBI), 
hypercholesterolemia, hypertension, seizures, thyroid disease, and other psychiatric disorders. 
All participants were matched on health variables, with the exception of MCI status (χ2=14.62, 
p= 0.001). Lastly, MoCA scores are included in the table to assess differences in global cognitive 
screening measure scores between depression groups. All participants were matched on MoCA 
scores, as no significant differences were found between groups. 
 3.1.1. Hypothesis I: Impact of Age and Health. It was expected in hypothesis I that 
chronic health deterioration is associated with both increasing age and depression status. It was 
expected that individuals with chronic health problems would be more likely to have current 
depressive symptoms or a history of diagnosed depression, and would be the older individuals in 
the study (Lenze et al, 2005; Moussavi et al, 2007; Cauley, 2012; McNicoll, 2012; Taylor, 
Aizenstein, & Alexopoulos, 2013). 
 3.1.1.1. Chronic Health is Associated with Depression Status. No significant 
associations were found using Kruskal Wallis analyses to assess the relationship between current 
and historical depression status and health deterioration, with the exception of MCI status 
(χ2=14.62, p = 0.001). Participants with current depression were more likely to also have 
clinically diagnosed MCI than participants with history of diagnosed depression but no current 
depression and those with no current or historical depression. 
 3.1.1.2. Health Deterioration in Aging. To identify the relationship between age and 
health, Pearson’s correlations were utilized. Individuals in this study range from 65-83 years of 
age. As individuals get older in the study sample, prevalence of MCI was more common 
(r=0.495, p < 0.001). No other significant associations were found between age and health 
variables (all p’s > 0.05). 
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3.2. Sleep Study. 
 Sleep measures include 7-day wrist actigraphy and self-report measures (SSS, PSQI, and 
ESS) for this study. 43 participants wore an actiwatch, all complete with 7 day actiwatch data. 50 
participants completed the ESS and PSQI. 37 participants completed the SSS. 
 3.2.1. Hypothesis II: Depressive Symptoms are Connected to Poorer Sleep Quality. 
Two multivariate GLM with covariate MCI status (clinically diagnosed positive or negative) and 
wrist actigraphy measures as dependent variables. Factors in different analyses included: current 
depression status from study 1 and study 2 and any depression from study 1 and study 2.  
For current depression, the current depression group (n=9) included participants that said 
“yes” for current depression from study 1 (query: yes/no choice; n=6) and participants that said 
“yes” for current depression from study 2 (query: yes/no choice for current; n=3). The control 
study 2 group included participants that said “no” for current depression from study 2 (n=22). 
This group EXCLUDED participants that have a history of diagnosed depression but no current 
depression (n=7 for study 2; unknown for study 1 binary query) and participants that indicated 
no current depression in study 1 (n=12) due to lack of information on history of diagnosed 
depression.  
For actigraphic sleep measures, a significant main effect of group showed that the current 
depression group had lower mean assumed sleep (F(1, 23) = 4.68, p = 0.041), lower mean actual 
sleep time (F(1, 23) = 4.34, p = 0.049), lower mean sleep efficiency (F(1, 23) = 11.62, p = 
0.002), higher mean sleep latency (F(1, 23) = 8.77, p = 0.007), and lower mean number of 
minutes immobile (F(1, 23) = 4.32, p = 0.049) than the control study 2 group. Table 4 shows 
estimated marginal means between the current depression group and the control study 2 group  
the standard error of the mean for each actigraphy variable. Figures 4 and 5 display mean 
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differences between the current depression and non-depressed (control study 2) groups in 
actigraphic measures of sleep efficiency and sleep latency, respectively. 
Table 4 
Actigraphy Variables for Current Depression vs. Control Study 2 Groups 
 
Variable Current Dep (n=7) Control Study 2* 
(n=19) 
p-value 
Mean Time in Bed 8.72  0.61 8.84  0.34 0.874 
Mean Assumed Sleep 6.89  0.55 8.35  0.31 0.041 
Mean Actual Sleep 
Time 
5.90  0.55 7.30  0.30 0.049 
Mean Actual Sleep % 86.42  3.12 87.92  1.72 0.698 
Mean Actual Wake 
Time 
0.55  0.27 0.82  0.15 0.413 
Mean Actual Wake 
% 
13.59  3.12 12.08  1.72 0.698 
Mean Sleep 
Efficiency 
68.12  3.66 83.42  2.02 0.002 
Mean Sleep Latency 1.20  0.27 0.21  0.15 0.007 
Mean Sleep Bouts 25.29  2.95 22.96  1.63 0.526 
Mean Wake Bouts 25.29  2.96 22.46  1.63 0.444 
Mean Sleep Bout 
Time 
0.17  0.04 0.24  0.02 0.192 
Mean Wake Bout 
Time 
0.02  0.006 0.03  0.003 0.323 
Mean Number of 
Minutes Immobile 
350.83  32.30 433.20  17.83 0.049 
Mean Immobile % 
Time 
81.64  3.53 84.79  1.95 0.476 
Mean Number of 
Minutes Moving 
69.90  18.64 80.97  10.29  0.633 
Mean Moving % 
Time 
18.36  3.53 15.23  1.95 0.477 
Mean Number of 
Immobile Phases 
45.79  4.78 38.91  2.64 0.253 
Mean Length 
Immobility 
8.49  2.45 12.64  1.35 0.181 
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14.32  2.72 
 
 




Mean One Minute 
Immobility % 
29.58  4.35 18.92  2.40 0.058 
Mean Fragmentation 
Index 
47.93  7.55 34.15  4.17 0.150 
Number of Days 
Actiwatch Worn 
6.35  0.37 6.82  0.20 0.313 
Note. x  y represents estimated marginal mean (EMM)  standard error of the mean (SEM), (n) 
= sample size. Table adjusted for covariate MCI status. 
*Control Study 2 group includes participants that indicated no current or historical depression in 
Study 2  
 
    
Figure 3. Actigraphy Measure of % Mean Sleep  Figure 4. Actigraphy Measure of Mean 
Efficiency in Currently Depressed and Non-  Sleep Latency in Currently Depressed and 
Depressed (Control Study 2) Groups.  Non-Depressed (Control Study 2) Groups.  
 
Regression analysis was used to investigate whether MCI status based on MoCA total 
score mediates the effect of current depression status on mean sleep efficiency (see Figure 3). In 
Step 1 of the mediation model, the regression of mean sleep efficiency on current depression 
status, ignoring the mediator, was significant, b = -18.26, t(30) = -5.19, p < 0.001. Step 2 showed 
that regression of the mean sleep efficiency on the mediator, MCI status based on MoCA score, 
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was not significant, b = 0.379, t(30) = 0.074, p = 0.942. Step 3 of the mediation process showed 
that the mediator, MCI status based on MoCA score, controlling for current depression status 
was significant, b = -2.52, t(31) = -2.21, p = 0.035. Step 4 of the analyses revealed that, 
controlling for the mediator MCI status based on MoCA score, current depression status was still 
a significant predictor of mean sleep efficiency, b = 18.36, t(31) = -5.71, p < 0.001. 
Approximately 51% of the variance in mean sleep efficiency was accounted for by the predictors 
(R2 = 0.51). The indirect effect was tested using a percentile bootstrap estimation approach with 
1000 samples.  
 
Figure 5. Standardized regression coefficients for the relationship between current depression 
status and mean sleep efficiency as mediated by MCI status based on MoCA total score.   
 
For any depression, the any depression group included participants that said “yes” for 
current depression from study 1 (query: yes/no choice; n=6), participants that said “yes” for 
current depression from study 2 (query: yes/no choice for current; n=3), and participants that 
answered “yes” for history of diagnosed depression from study 2 (query: yes/no choice for 
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history; n=7). The control study 2 group included participants that said “no” for current 
depression from study 2 (n=22). This group EXCLUDED participants that indicated no current 
depression in study 1 (n=12) due to lack of information on history of diagnosed depression. 
Results showed that the any depression group and the control study 2 group showed no 
significant differences in objective sleep as measured by wrist actigraphy over a 7 day period. 
3.2.1.1. Subjective Measures of Sleep will Reflect Objective Measures. Correlational 
analyses were used to assess the relationship between subjective and objective sleep measures 
between the current depression group and the control study 2 group. Results showed a negative 
correlation between PSQI Component 7: daytime dysfunction and mean assumed sleep (r = -
0.57, p < 0.001), mean actual sleep time (r = 0.53, p < 0.001), mean sleep efficiency (r = -0.49, p 
= 0.001), and mean number of minutes immobile (r = -0.54, p < 0.001). This means that 
participants that reported more daytime dysfunction on the PSQI had lower mean assumed sleep, 
lower mean actual sleep time, lower mean sleep efficiency, and lower mean number of minutes 
immobile as measured by wrist actigraphy. Results also showed that the actigraphic measure of 
mean sleep latency was positively correlated with Stanford Sleepiness Scale (SSS) average score 
(r = 0.39, p = 0.018), PSQI Component 2: sleep latency (r = 0.40, p = 0.007), PSQI Component 
6: use of sleeping medication (r = 0.40, p = 0.007), and PSQI composite score (r = 0.39, p = 
0.009). This means that participants that showed longer sleep latency through actigraphy also 
reported more daytime sleepiness, longer sleep latency, greater use of sleeping medication, and 
an overall greater amount of sleep problems. Finally, results showed that the actigraphic measure 
of mean sleep efficiency negatively correlated with PSQI Component 5: sleep disturbances (r = -
0.33, p = 0.028) and PSQI composite score (r = -0.33, p = 0.034). This means that participants 
 69 
that showed lower sleep efficiency through actigraphy also reported more sleep disturbances and 
an overall greater amount of sleep problems. 
Following correlational analyses, a multivariate GLM with covariate MCI status 
(clinically diagnosed positive or negative) and self-report sleep measures (SSS, ESS, PSQI) as 
dependent variables was run to assess differences in self-reported sleep between current 
depression group and control study 2 group. Results showed that the current depression group 
reported more sleep problems and sleepiness than the no depression group. The current 
depression group reported a trend toward higher average scores on the Stanford Sleepiness Scale 
(SSS) (M=1.84, SE=0.16) than the control study 2 group (M=1.45, SE=0.093; p = 0.059). The 
current depression group reported higher scores on PSQI Component 5: sleep disturbances 
(M=1.89, SE=0.21) than the control study 2 group (M=0.95, SE=0.12; p = 0.001). The current 
depression group reported higher scores on PSQI Component 7: daytime dysfunction (M=1.55, 
SE=0.26) than the control study 2 group (M=0.23, SE=0.15; p > 0.001). Table 5 shows the 
estimated marginal means between the current depression group and the control study 2 group  
the standard error of the mean for each self-report sleep variable. 
Table 5 
Self-Report Sleep Variables in Current Depression vs. Control Study 2 Groups 
Variable Current Dep (n=9) No Dep* (n=22) p-value 
SSS Average Score 1.84  0.16 1.45  0.09 0.059 
ESS Total Score 4.12  1.22 4.27  0.71 0.922 
ESS Average Score 0.52  0.15 0.54  0.09 0.923 
PSQI Component 1: 
Subjective Sleep 
Quality 
0.88  0.25 0.50  0.15 0.231 
PSQI Component 2: 
Sleep Latency 
1.47  0.37 1.17  0.22 0.523 
PSQI Component 3: 
Sleep Duration 
0.34  0.24 0.72  0.14 0.220 
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0.83  0.32 
 
0.57  0.19 
 
0.525 
PSQI Component 5: 
Sleep Disturbances 
1.89  0.21 0.95  0.12 0.001 
PSQI Component 6: 
Use of Sleeping 
Medication 
0.74  0.34 1.06  0.20 0.466 
PSQI Component 7: 
Daytime Dysfunction 
1.55  0.26 0.23  0.15 <0.001 
PSQI Composite 
Score 
7.71  1.11 5.21  0.65 0.084 
Note. x  y represents estimated marginal mean (EMM)  standard error of the mean (SEM), (n) 
= sample size. Table adjusted for covariate MCI status. 
SSS=Stanford Sleepiness Scale; ESS=Epworth Sleepiness Scale; PSQI=Pittsburgh Sleep Quality 
Index 
*Control Study 2 group includes participants that indicated no current or historical depression in 
Study 2 
 
Finally, linear regression was run to assess possible objective and self-report sleep 
variables that impacted CES-D total scores in Study 2. A simple linear regression was calculated 
to predict CES-D total score based on MCI status (clinically diagnosed positive or negative), 
Stanford Sleepiness Scale (SSS) average score, and PSQI Component 7: daytime dysfunction 
score. A significant regression equation was found (F (3, 18) = 12.26, p < 0.001), with an R2 of 
0.67. It was found that SSS average score significantly predicted CES-D total score (β  = 6.18, p 
= 0.017), as did PSQI Component 7: daytime dysfunction (β = 1.05, p = 0.002) and a trend 
toward MCI status (β = 5.37, p =0.056). A simple linear regression was calculated to predict 
CES-D total score based on MCI status (clinically diagnosed positive or negative) and PSQI 
composite score. A significant regression equation was found (F (2, 29) = 4.47, p = 0.020), with 
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an R2 of 0.24. It was found that PSQI composite score significantly predicted CES-D total score 
(β  = 0.75, p = 0.010). 
3.2.1.2. Depressive History will Impact Sleep Quality. Multivariate GLM with covariate 
MCI status (clinically diagnosed positive or negative) was examined using self-report sleep 
measures (SSS, ESS, PSQI) and wrist actigraphy as dependent variables and historical diagnosed 
depression status (binary; yes/no) as factor. History of diagnosed depression group (n=9) 
includes participants that answered “yes” for history of diagnosed depression from study 2 
(query: yes/no choice for history). This group includes two participants that also endorsed 
current depression. Control study 2 group includes participants that answered “no” for history of 
diagnosed depression from study 2 (n=22). One participant endorsed current depression but did 
not report a history of diagnosed depression and was excluded from analyses. For actigraphic 
sleep measures, a significant main effect of group showed that the history of diagnosed 
depression group had higher mean actual sleep time (F(1, 24) = 6.08, p = 0.021), higher mean 
sleep bout time (F(1, 24) = 5.96, p = 0.022), higher mean number of minutes immobile (F(1, 24) 
= 5.65, p = 0.026), and higher mean length immobility (F(1, 24) = 5.40, p = 0.029). Table 6 
shows the estimated marginal means between the history of diagnosed depression group and the 
control study 2 group  the standard error of the mean for each actigraphy variable. 
Table 6  
Actigraphy Variables for History of Diagnosed Depression vs. Control Study 2 Groups 
 
Variable History of Dep (n=8) Control Study 2* 
(n=19) 
p-value 
Mean Time in Bed 9.55  0.37  8.74  0.24  0.076 
Mean Assumed Sleep 9.16  0.38  8.31  0.24  0.071 
Mean Actual Sleep 
Time 
8.39  0.37 7.31  0.24  0.021 
Mean Actual Sleep % 91.45  1.70  88.41  1.10  0.148 
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Mean Actual Wake 
Time 
0.57  0.18  0.76  0.12  0.407 
Mean Actual Wake 
% 
8.55  1.70  11.59  1.10  0.148 
Mean Sleep 
Efficiency 
87.70  1.80 83.96  1.17  0.095 
Mean Sleep Latency 0.15  0.03  0.15  0.02 0.897 
Mean Sleep Bouts 20.35  2.53 23.00  1.64 0.389 
Mean Wake Bouts 19.70  2.52 22.48  1.63 0.365 
Mean Sleep Bout 
Time 
0.90  0.23 0.23  0.15 0.022 
Mean Wake Bout 
Time 
0.03  0.004 0.03  0.002 0.721 
Mean Number of 
Minutes Immobile 
497.17  22.50 433.23  14.56  0.026 
Mean Immobile % 
Time 
88.22  2.13 85.15  1.38 0.238 
Mean Number of 
Minutes Moving 
65.97  13.66 78.16  8.83 0.463 
Mean Moving % 
Time 
11.78  2.13 14.87  1.38 0.236 
Mean Number of 
Immobile Phases 
37.84  4.45 38.53  2.88 0.896 
Mean Length 
Immobility 
43.15  11.08 12.38  7.17 0.029 
Mean One Minute 
Immobility 
7.04  1.46 7.93  0.94 0.614 
Mean One Minute 
Immobility % 
15.58  1.98 18.47  1.28 0.234 
Mean Fragmentation 
Index 
27.36  3.97 33.34  2.57 0.219 
Number of Days 
Actiwatch Worn 
7.00  0.14  6.90  0.09 0.555 
Note. x  y represents estimated marginal mean (EMM)  standard error of the mean (SEM), (n) 
= sample size. Table adjusted for covariate MCI status. 
*Control Study 2 group includes participants that indicated no current or historical depression in 
Study 2  
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For self-report sleep measures (SSS, ESS, PSQI), results revealed that the history of 
diagnosed depression group reported more sleep problems than the no depression group. The 
history of diagnosed depression group reported higher scores on PSQI Component 1: subjective 
sleep quality (M=1.09, SE=0.20) than the control study 2 group (M=0.46, SE=0.13; p = 0.016). 
The history of diagnosed depression group reported higher scores on PSQI Component 5: sleep 
disturbances (M=1.44, SE=0.11) than the control study 2 group (M=1.05, SE=0.07; p = 0.007). 
Table 7 shows the estimated marginal means between the history of diagnosed depression group 
and the control study 2 group  the standard error of the mean for each self-report sleep variable. 
Table 7 
Self-Report Sleep Variables in Current Depression vs. Control Study 2 Groups 
Variable Current Dep (n=9) No Dep* (n=22) p-value 
SSS Average Score 1.84  0.16 1.45  0.09 0.059 
ESS Total Score 4.12  1.22 4.27  0.71 0.922 
ESS Average Score 0.52  0.15 0.54  0.09 0.923 
PSQI Component 1: 
Subjective Sleep 
Quality 
0.88  0.25 0.50  0.15 0.231 
PSQI Component 2: 
Sleep Latency 
1.47  0.37 1.17  0.22 0.523 
PSQI Component 3: 
Sleep Duration 
0.34  0.24 0.72  0.14 0.220 
PSQI Component 4: 
Habitual Sleep 
Efficiency 
0.83  0.32 0.57  0.19 0.525 
PSQI Component 5: 
Sleep Disturbances 
1.89  0.21 0.95  0.12 0.001 
PSQI Component 6: 
Use of Sleeping 
Medication 
0.74  0.34 1.06  0.20 0.466 
PSQI Component 7: 
Daytime Dysfunction 
1.55  0.26 0.23  0.15 <0.001 
PSQI Composite 
Score 
7.71  1.11 5.21  0.65 0.084 
Note. x  y represents estimated marginal mean (EMM)  standard error of the mean (SEM), (n) 
= sample size. Table adjusted for covariate MCI status. 
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SSS=Stanford Sleepiness Scale; ESS=Epworth Sleepiness Scale; PSQI=Pittsburgh Sleep Quality 
Index 
*Control Study 2 group includes participants that indicated no current or historical depression in 
Study 2 
 
3.3. Neurocognitive Output Measures. 
 The 1-month neurocognitive assessment was used to assess the status of various cognitive 
domains (including, but not limited to: immediate and delayed visuospatial and verbal memory, 
working memory, episodic memory, and psychomotor speed) in all participants. Both raw scores 
and age-adjusted scores on neurocognitive assessments were used in analyses and produced 
identical results. In addition, memory was tested using a unique testing procedure during pre- 
and post-sleep period called overnight memory consolidation (Walker, 2002) during night 1 of 
the sleep study. 
3.3.1. Hypothesis III: Current Depressive Symptoms Impair Cognition. As 
depression is associated with cognitive impairment particularly in processing speed, visuospatial 
abilities, episodic memory, verbal fluency, executive functioning, and learning/free recall on 
memory tests (Dotson, Beydoun, & Zonderman, 2010; Lenze et al., 2018), this hypothesis 
predicts that participants with current depression will perform significantly worse on tasks 
assessing these cognitive domains. 
 Neurocognitive status analyses between the current depression group (n=9) and the 
control study 2 group (n=22) revealed significant findings for overnight procedural memory, 
verbal learning/recall, and visuospatial abilities but in the opposite direction than expected. On 
the overnight memory consolidation task, the current depression group performed better than the 
no depression group. The current depression group had a greater speed for correct sequences per 
trial at night (M=16.10, SE=5.90) than the control study 2 group (M=34.45, SE=3.47; F(1, 22) = 
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6.50, p = 0.018). The current depression group showed a trend toward higher total taps through 
12 trials in the morning (M=536.92, SE=61.41) than the control study 2 group (M=382.64, 
SE=36.12; F (1, 22) = 4.25, p = 0.051). The current depression group had higher average correct 
taps per trial in the morning (M=41.80, SE=5.36) than the control study 2 group (M=27.54, 
SE=3.15; F(1, 22) = 4.76, p = 0.040). The current depression group had higher average taps per 
trial in the last 3 trials in the morning (M=47.99, SE=5.70) than the control study 2 group 
(M=32.32, SE=3.35; F(1, 22) = 5.09, p = 0.034). The current depression group had a trend 
toward higher average correct sequences in the last 3 trials in the morning (M=8.30, SE=1.09) 
than the control study 2 group (M=5.65, SE=0.64; F(1, 22) = 3.95, p = 0.059). The current 
depression group had higher average taps per trial in the last 6 trials in the morning (M=47.93, 
SE=5.46) than the control study 2 group (M=32.89, SE=3.21; F(1, 22) = 5.10, p = 0.034). The 
current depression group had a greater percent improvement of correct taps between night and 
morning (M=131.45, SE=101.21) than the control study 2 group (M= -138.74, SE=59.53; F(1, 
22) = 4.80, p =0.039). 
 On the one-month follow-up neurocognitive measures, the current depression group also 
performed significantly better than the no depression group. The current depression group had 
higher raw scores for total recall on the HVLT-R (M=23.68, SE=2.00) than the control study 2 
group (M=17.90, SE=1.42; F(1, 19) = 4.64, p = 0.44). Also, the current depression group had 
higher raw scores on Trial 1 of the BVMT-R (M=5.98, SE=0.71) than the control study 2 group 
(M=2.78, SE=0.41; F(1, 15) = 25.04, p = 0.002). However, the current depression group did 
perform significantly worse on the MoCA Attention component (M=4.75, SE=0.28) than the 
control study 2 group (M=5.65, SE=0.16; F(1, 28) = 6.81, p=0.014). No other neurocognitive 
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measures produced significant group differences between the current depression group and the 
control study 2 group (p’s > 0.05). 
 Regression analysis was used to investigate whether MCI status based on MoCA score 
mediates the effect of current depression status on MoCA Attention score (see Figure 6). In Step 
1 of the mediation model, the regression of MoCA Attention score on current depression status, 
ignoring the mediator, was significant, b = -0.67, t(36) = -2.38, p = 0.023. Step 2 showed that 
regression of MocA Attention score on the mediator, MCI status based on MoCA score, was 
significant, b = 0.12, t(35) = 3.55, p = 0.001. Step 3 of the mediation process showed that the 
mediator, MCI status based on MoCA score, controlling for current depression status was 
significant, b = -3.49, t(36) = -2.90, p = 0.006. Step 4 of the analyses revealed that, controlling 
for the mediator MCI status based on MoCA score, current depression status was still a 
significant predictor of MoCA Attention score, b = -1.10, t(36) = -3.79, p < 0.001.  
Approximately 29% of the variance in mean sleep efficiency was accounted for by the predictors 






Figure 6. Standardized regression coefficients for the relationship between current depression 
status and MoCA Attention score as mediated by MCI status based on MoCA total score 
 
Finally, linear regression was run to assess possible neurocognitive variables that 
impacted CES-D total scores in Study 2. A simple linear regression was calculated to predict 
CES-D total score based on MCI status (clinically diagnosed positive or negative), BVMT-R 
total recall raw score, and BVMT-R delayed recall raw score. A significant regression equation 
was found (F (3, 15) = 4.45, p = 0.020), with an R2 of 0.47. It was found that MCI status 
significantly predicted CES-D total score (β  = 15.64, p = 0.034). 
 3.3.1.1. Historical Depressive Symptoms Impair Cognition. Neurocognitive status 
analyses were also conducted between the history of diagnosed depression group (n=9) and the 
control study 2 group (n=22). These analyses revealed significant findings for verbal learning 
and episodic memory but in the opposite direction than expected. On the overnight memory 
consolidation task, the history of diagnosed depression group and the control study 2 group 
showed no significant differences on any task variable (all p’s > 0.05). For the neurocognitive 
follow-up, the history of diagnosed depression group performed better on HVLT-R for total 
recall and delayed recall than the no depression group. The history of diagnosed depression 
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group had higher raw scores for total recall on the HVLT-R (M=26.00, SE=2.26) than the control 
study 2 group (M=20.07, SE=1.34; F(1, 16) = 5.01, p = 0.040). The history of diagnosed 
depression group also had higher raw scores for delayed recall on the HVLT-R (M=9.79, 
SE=1.32) than the control study 2 group (M=6.29, SE=0.78; F(1, 16) = 5.11, p = 0.038). No other 
neurocognitive measure produced significant group differences between the history of diagnosed 
depression group and the control study 2 group (p’s > 0.05). 
3.4. MCI Diagnosis 
 Hypothesis IV posited that aging participants who display symptoms of current 
depression will have a higher incidence of aMCI. Thirty-eight recruited participants were 
assessed for MCI status, resulting in current depression group from study 1 and study 2 (n=9), 
history of diagnosed depression but no current depression group from study 2 (n=7), and a 
sociodemographically similar group without current or historical depression from study 2 
(Control 2; n=22). Participants from study 1 who endorsed no current depression (n=12) were 
excluded from analyses due to lack of information on historical depression status. 
 3.4.1. Hypothesis IV: Higher Incidence of MCI in Depressed Older Adults. 
Correlational analyses were used to assess the percentage of participants in each of three groups 
that have clinically diagnosed MCI. In the history of diagnosed depression but no current 
depression group, 0 participants of 7 (0%) were diagnosed with MCI. In Control Study 2 group, 
2 participants of 22 (9%) were diagnosed with MCI. In the current depression group, 6 
participants of 9 (67%) were diagnosed with MCI. Post-hoc tests reveal significant differences in 
MCI status between the current depression group vs. control study 2 group (p=0.003) and the 
current depression group vs. the history of diagnosed depression but no current depression group 
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(p=0.003). There were not significant differences between the control study 2 and the history of 
diagnosed depression but no current depression groups (p>0.05).  
3.5. Cognitive Reserve. 
 Hypothesis V proposed that cognitive reserve (assessed based on IQ correlates such as 
the WAIS-III vocabulary subtest and AMNART) would be associated with higher cognitive 
performance regardless of current or historical depression status. Cognitive reserve measures 
were only employed in Study 2 so participants from Study 1 were not evaluated. Twenty 
participants were included in analyses including participants with current depression (n=2), 
history of diagnosed depression but no current depression (n=4), and control study 2 (n=16). 
 3.5.1. Hypothesis IV: Cognitive Reserve Moderates Levels of Cognitive Impairment. 
Correlational analyses were used to assess if education was significantly correlated with 
depression status (current depression and history of diagnosed depression). No significant 
correlations were found between education level and current or historical depression status (p’s > 
0.05). Correlational analyses were then used to assess the relationship between cognitive reserve 
proxy measures (WAIS-III vocabulary subtest and AMNART) and other neurocognitive 
measures. Results showed significant positive correlations between AMNART performance and 
HVLT-R delayed recall raw score (r = 0.50, p = 0.026), BVMT-R total recall raw score (r = 
0.49, p = 0.035), and BVMT-R delayed recall raw score (r = 0.48, p = 0.038). This means that 
participants that performed better on the AMNART also performed better on HVLT-R delayed 
recall and BVMT-R total and delayed recall. Results also showed significant positive 
correlations between WAIS-III vocabulary subtest performance and HVLT-R total recall raw 
score (r = 0.63, p = 0.03), HVLT-R delayed recall raw score (r = 0.66, p = 0.002), HVLT-R 
retention percentage from learning trials to delayed recall (r = 0.55, p = 0.012), Boston Naming 
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Test total score (r = 0.53, p = 0.017), BVMT-R total recall raw score (r = 0.77, p < 0.001), 
BVMT-R learning raw score (r = 0.60, p = 0.007), and BVMT-R delayed recall raw score (r = 
0.72, p < 0.001). This means that participants that performed better on the WAIS-III vocabulary 
subtest also performed better on HVLT-R total, delayed recall, and retention percentage, Boston 
Naming total score, and BVMT-R total, learning, and delayed recall. No significant correlations 
were found between cognitive reserve proxy measures and overnight memory consolidation 
performance (p’s > 0.05). 
 Three multivariate GLM with covariate MCI status (clinically diagnosed positive or 
negative) was examined using cognitive reserve proxy measures (WAIS-III vocabulary subtest 
and AMNART) as dependent variables and depression status as a factor. The groups for each 
analysis are as follows: 1) current depression vs. no depression, 2) history of diagnosed 
depression vs. no depression, and 3) any depression (current or historical) vs. no depression. For 
all analyses, results revealed that there were no significant differences between groups on 













Sleep quality and depression status are closely associated in aging, with sleep disturbance 
or sleep disorder being a primary symptom of late-life depression (5th ed, DSM, American 
Psychiatric Association, 2013). Sleep disturbance, including persistent insomnia, may even 
continue after effective treatment for other symptoms of depression (Nutt, Wilson, & Paterson, 
2008; Pigeon et al, 2008). In addition, a strong association exists between late-life depression, 
cognitive impairment, and poor cognitive outcomes, including risk of MCI and dementia 
(Sheline et al, 2006; Saczynski et al, 2010; Liu et al, 2017). The directionality and mechanisms 
underlying this association are, however, poorly understood. 
 The purpose of this thesis was to explore associations between current and historical 
depression status, sleep quality, and cognitive ability in a sample of older adults with normal 
cognition or MCI diagnosis. It was hypothesized that positive current or historical depression 
status is significantly related to cognitive impairment and sleep disturbance.  Sleep disturbance 
as subjectively interpreted from participants’ self-report and objectively from actigraphy were 
shown to be significantly associated with depression status in this study. Relationships between 
current depression and MCI status were shown, however depressed participants did not display 
impairment on cognitive measures, such as verbal and visuospatial memory, and overnight 
memory consolidation as expected. 
4.1. Depression & Sleep Parameters. 
 Predictions were made regarding the relationship between depression status and self-
report and objective sleep measures. Various measures were collected to assess sleep 
fragmentation (PSQI, actigraphy) and sleep deprivation (ESS, SSS). It was hypothesized that 
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participants with current depressive symptoms and/or a history of diagnosed depression would 
show and self-report poorer sleep quality. Results showed that participants that had current 
depression had poorer sleep than participants with no depression with lower mean assumed 
sleep, lower mean actual sleep time, lower sleep efficiency, longer sleep latency, and lower mean 
number of minutes immobile (as measured by wrist actigraphy). Participants with current 
depression also reported more sleep disturbances and greater daytime dysfunction on the PSQI 
and a trend toward greater average sleepiness on the SSS, when compared with participants with 
no depression. These results are in line with previous literature (Benca, Obermeyer, Thisted, & 
Gillin, 1992; Carney, Segal, Edinger, & Krystal, 2007; Dombrovski et al, 2007; Nutt et al, 2008). 
 Participants with a history of diagnosed depression but no current depression did not 
show sleep disturbance in actigraphy. The history of diagnosed depression group actually had 
higher mean actual sleep time, longer mean sleep bout time, higher mean number of minutes 
immobile, and longer mean length immobility than the no depression group. However, the 
history of diagnosed depression group did report poorer subjective sleep quality and more sleep 
disturbances on the PSQI than the no depression group. Some evidence exists in previous 
literature of older adults with a history of diagnosed depression in remission showing greater 
incidence of sleep disturbance through self-report and diagnostic interview (Motivala, Levin, 
Oxman, & Irwin, 2006). In actigraphy, the history of diagnosed depression group may have been 
displaying recurrent symptoms of hypersomnia, or excessive time spent sleeping, which is a less 
common symptom of major depression but may also continue after effective treatment (Franzen 
& Buysse, 2008). 
It should also be noted that most literature on historical depression in older adults focuses 
on participants that have relapsed in their depression, with a major focus on persistent insomnia 
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(Mallon, Broman, & Hetta, 2000; Carney, Segal, Edinger, & Krystal, 2007; Dombrovski et al., 
2007). Lack of expected actigraphy results may alternatively be explained by the fact that 
participants in the history of diagnosed depression group for this study were not currently 
experiencing depression symptoms and did not display or report significant insomnia. There is a 
gap in the literature exploring older adults with history of diagnosed depression but no current 
symptoms. 
4.2. Cognitive Status and Health in Aging. 
 Health parameters and cognitive performance reflecting pathological cognitive decline in 
aging were explored in this study. As shown in previous literature, chronic health problems were 
expected to be associated with increased age and comorbidity with depression. In addition, 
individuals with current depression or history of diagnosed depression were hypothesized to have 
impairment in various cognitive domains including processing speed, episodic memory and 
language, verbal and visuospatial memory, and memory consolidation, all probed in 
neurocognitive assessment during the study. Results are explained and explored below. 
 4.2.1. Health & Depression. Individuals with current or historical depression often have 
comorbid common health conditions including cerebrovascular disease, cardiovascular disease, 
and diabetes (Lenze et al, 2005; Moussavi et al, 2007; Taylor, Aizenstein, & Alexopoulos, 2013). 
Health conditions were compared between groups with current depression, and history of 
diagnosed depression but no current depression, and no depression. Results showed no 
significant differences between groups on health variables, with the exception of MCI. 
Participants with current depression were more likely to also have clinically diagnosed MCI than 
participants with a history of diagnosed depression but no current depression and those with no 
depression history. As this study was designed to assess the relationship between sleep and 
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cognitive status in depression, a protocol was made to attempt to create similar participant 
groups so as to limit variance from other sources. It may therefore be beneficial to have no 
significant findings on other health variables, indicating groups were matched on health status. 
The comorbidity of current depression and poor cognitive outcomes such as MCI diagnosis was 
expected and supported by the literature (Green et al, 2003; Lenze et al, 2018).  
In general, chronic health conditions become more of a commonality as individuals grow 
older (Cauley, 2012; McNicoll, 2012). It was predicted that in our sample of 65-83 year old 
individuals, increased age would be associated with a greater number of health complications. 
The only health decline parameter associated with increased age in this participant sample was 
MCI diagnosis. Analyses showed that individuals with diagnosed MCI are older than non-
diagnosed comparison participants. Depression groups were matched on health status with the 
exception of MCI, which was more prevalent in the current depression group. Therefore, a 
potential explanation for the absence of increased health complications in older individuals is 
that the older individuals are concentrated in the current depression group, and the younger in the 
other two groups. As these three groups are matched, health complications may have been 
matched between “older” (i.e. current depression group) and “younger” (i.e. history of diagnosed 
depression and no depression groups). 
4.2.2. Paradoxical Cognitive Findings. Common cognitive deficits exhibited in late-life 
depression include worse performance in processing speed, visuospatial abilities, episodic 
memory, verbal fluency, and executive dysfunction, as well as poor learning and free recall on 
memory tests (Dotson, Beydoun, & Zonderman, 2010). The presence of major depression, both 
currently and historically, shows accelerated cognitive decline in dementia that is greater than 
expected for age and education level (Rapp et al, 2011). It was expected that individuals who 
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endorsed current depression or a history of diagnosed depression would perform more poorly on 
neurocognitive tests that assessed these domains. These results were not found.  
Participants with current depression actually performed better on various overnight 
memory consolidation task variables (i.e. speed for correct sequences per trial at night, total taps 
through 12 trials in morning, average correct taps per trial in morning, average taps per trial in 
the last 3 trials in morning, average correct sequences in the last 3 trials in morning, average taps 
per trial in the last 6 trials in the morning, percent improvement of correct taps between night and 
morning) than participants with no depression. There may be several reasons for the lack of 
impairment on the overnight memory consolidation task by the current depression group. This 
task has not been explored in depression before since the paradigm is novel. In addition, 
procedural memory has not been explored as a cognitive deficit in previous literature. 
Surprisingly, the current depression group also performed better on some neurocognitive follow-
up measures, including HVLT-R total recall and Trial 1 of the BVMT-R, than the no depression 
group. Participants with current depression may not have displayed cognitive impairment on the 
verbal and visuospatial tasks as expected because their depression was at a subclinical level and 
had not yet affected cognition. Current depression was assessed through endorsement (positive 
or negative) in study 1 and study 2. This was not a clinical grade diagnosis and assessment. In 
addition, the majority of literature on depression and cognitive impairment in older adults 
assesses depression at a clinical level. 
 Participants with a history of diagnosed depression performed better on neurocognitive 
follow-up measures, including HVLT-R total recall and HVLT-R delayed recall, than 
participants with no depression. History of diagnosed depression and its effect on cognitive 
performance has seldom been explored in the literature. The hypothesis on the connection 
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between history of diagnosed depression and cognitive impairment was primarily made based on 
prospective studies in the literature that explored rates of cognitive decline in older adults that 
had dementia as a function of historical major depression (Geerlings et al, 2008; Rapp et al, 
2011). No participant in this study had dementia and this study was not prospective.  
 One area of cognition that the current depression group did show impairment on, when 
compared with the no depression group, was attention. The current depression group performed 
significantly worse on the MoCA Attention component than the no depression group. This result 
is supported by literature showing that individuals with major depression are likely to have an 
attention deficit (Veiel, 1997; Paelecke-Habermann, Pohl, & Leplow, 2005; Rock, Roiser, 
Riedel, & Blackwell, 2014). It is interesting that the relationship between depression and 
attention was picked up on a subclinical level. 
4.3. Cognitive Reserve.  
Cognitive reserve is a functional assessment that focuses on individual differences in 
efficiency when performing cognitive tasks or information processed and is known to be 
protective of AD and related conditions (Stern, 2002). It was expected that cognitive reserve 
(measured through education level and IQ correlates such as the vocabulary subtest of the 
WAIS-III and AMNART) would be correlated with higher scores on neurocognitive 
assessments, regardless of current or historical depression status. Results showed no significant 
relationship between cognitive reserve measures and current or historical depression or education 
level and current or historical depression, as expected. In addition, results showed that 
participants that scored higher on cognitive reserve proxy measures also scored higher on various 
neurocognitive follow-up measures including: HVLT-R total recall, HVLT-R delayed recall, 
HVLT-R retention percentage from learning trials to delayed recall, BVMT-R total recall, 
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BVMT-R delayed recall, BVMT-R learning, and Boston Naming total score. These results were 
in line with what was hypothesized. 
4.4. Mediational Models. 
 Mediational models were constructed to assess whether MCI status mediated the 
relationship between current depression status and different sleep variables and cognitive 
variables. Two significant models were made. For Model 1, it was found that MCI status 
partially mediated the relationship between current depression status and the actigraphic measure 
of mean sleep efficiency. Few studies have looked at depression, sleep, and cognition together 
despite evidence that poor sleep is closely related to depression (Sbarra & Allen, 2009) and sleep 
disorder and depressive symptoms are both independently associated with cognitive impairment 
(Riemann, Berger, & Voderholzer, 2001; Naismith, Norrie, Lewis, Scott, & Hickie, 2009; 
Koehler, Thomas, Barnett, & O’Brien, 2010; Smagula et al., 2013; Snyder, 2013). Previous 
literature has shown that depression has a significant impact on the relationship between sleep-
wake patterns and cognition (Mellor et al, 2018). There is a gap in the literature exploring the 
impact cognitive status has on the relationship between depression and sleep, shown in this 
model. 
 For Model 2, it was found that MCI status partially mediated the relationship between 
current depression status and MoCA Attention scores. MCI status in this model was based on 
total MoCA score so it stands to reason that total score on the MoCA would be related to a score 
on a component of the test. And, as previously mentioned, the literature supports the relationship 
between attention and depression with individuals positive for depression being more likely to 
have an attention deficit (Veiel, 1997; Paelecke-Habermann, Pohl, & Leplow, 2005; Rock, 
Roiser, Riedel, & Blackwell, 2014). 
 88 
4.5. Methodological Strengths and Limitations.  
 A major strength of this study is that it addresses several gaps in the literature including 
assessment of both current and historical depression status in older adults, as well as exploration 
of preclinical markers of cognitive decline in participants that predominantly have normal 
cognition. With most studies ignoring the presence of historically diagnosed depression, this 
study can provide new insight into how current vs. historical depression impacts sleep and 
cognition. In addition, literature exploring cognition and depression typically looks at a 
demented sample or are prospective for dementia onset in a depressed sample. This study is 
novel in its assessment of older adults with normal cognition, who make up the majority of the 
study sample (n=38). In order to minimize confounding influences, recruitment sites and 
strategies and careful interview were used to match the current depression, history of diagnosed 
depression but no current depression, and no depression groups on demographic and health 
characteristics. As a result, this study was able to reduce the impact of important demographic 
factors such as education, race, and marital status, as well as health factors including OSA, 
cardiovascular disease, cerebrovascular disease, etc. on variance in the findings. MCI status was, 
however, found to be significantly different between groups and was therefore used as a 
covariate in statistical analyses. 
 This study is both complicated and time consuming, including home visits and sleep 
equipment, which may have played a part in our total number of accrued patients. In addition, a 
number of interested older adults were too young to participate or living at a distance not feasible 
for the 3-4 visits required per participant. The exclusion of these individuals severely depleted 
the total N for this study. As there is a relatively low N, all results should be deemed preliminary. 
 89 
There was also a very low n for depression groups with the majority of participants not endorsing 
current depression. 
 A major limitation of this study was the fact that it was not designed to study depression. 
This study was designed to explore sleep parameters in older adults with and without clinically 
diagnosed MCI. The factor of depression was explored as a secondary study. It should be 
clarified that in Study 1 (pilot study), depression was probed only through a yes/no question on 
the demographic interview regarding if the participant felt that he/she was currently depressed. 
The assessment of depression was expanded in Study 2 to include measures of depression 
severity (i.e. CES-D), depression medication use, and history of diagnosed depression (i.e. 
supplemental questions). Since different depression measures were used in Study 1 and Study 2, 
this made post-hoc groups complex and problematic. Analyses excluded participants from Study 
1 that did not endorse current depression as history of diagnosed depression and depression 
medication use was unknown for these participants. I plan to continue exploring depression in 
this study and when my N grows to a more reasonable size, I can exclude Study 1 data from 
analyses to simplify analyses. 
4.6. Conclusion. 
 This thesis study investigated the hypothesis that depression status may have an 
important negative impact on sleep quality and cognitive function. Overall, current depression 
was significantly associated with poorer objective and self-reported sleep quality. History of 
diagnosed depression was also associated with poorer self-reported sleep quality. Findings were 
not consistent with the hypothesis that depression status (current or historical) would be 
associated with impairment on neurocognitive measures. In fact, participants with current or 
historical depression performed better on neurocognitive tasks assessing verbal learning and 
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memory and visuospatial abilities. The only cognitive impairment associated with depression 
status was in attention. Due to the low N and discrepancy in depression measures, these results 
can only be considered preliminary and warrant further exploration. Continuation of this study 
and future research into the connection between depression status, cognition, and sleep quality 
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APPENDIX B: SUPPLEMENTAL QUESTIONS ON DEPRESSIVE HISTORY 
 
1. Have you ever thought you may be depressed at any point in your life? 
 
 
2. Have you ever been formally diagnosed with depression at any point in your life? 
 
 
3. When did you first experience depressive symptoms? 
 
 
4. For how long did you experience these depressive symptoms? 
 
 
5. Have you ever taken medication for depression? If so, what medication did you take? 
When did you start and for how long did you take this medication? 
 
 
6. Are you still experiencing any symptoms of depression? Do you take medication for 
these symptoms currently? 
 
 
7. Have you ever experienced any other types of mental health issues (e.g. bipolar disorder, 
schizophrenia, or related disorders, etc.)? If so, what are they? Do you feel you struggle 




















































APPENDIX E: AMERICAN NATIONAL ADULT READING TEST 
Use the following script when introducing the AMNART: 
 
I want you to read slowly down the list of words starting here (indicate first word) and 
continuing down this column and onto the next. After each word please wait until I say 
‘Next’ before reading the next word. I must warn you that there are many words that you 
probably won’t recognize; in fact, most people don’t know them, so just guess at these, ok? 
Go ahead. 
 
The examinee should be encouraged to guess and all responses should be reinforced (“good”, 
“that’s fine”, etc.). The examinee may change response if he or she wishes to do so but if more 



































ACHE        CHASSIS 
AISLE        CELLIST 
CAPON        ALGAE 
DEBT        SUPERFLUOUS 
CHORD        CHAMOIS 
HEIR         THYME 
DENY         APROPOS  
BOUQUET        VIRULENT 
CAPRICE        ZEALOT 
GAUGE        FACADE 
WORSTED        CABAL 
DEPOT        ABSTEMIOUS 
NAUSEA        DETENTE 
NAIVE        SCION 
SUBTLE        PAPYRUS 
PUGILIST        QUADRUPED  
FETAL        PRELATE 
BLATANT        EPITOME 
PLACEBO        BEATIFY 
HIATUS        HYPERBOLE 
SIMILE        IMBROGLIO  







































APPENDIX J: DEMOGRAPHIC QUESTIONS 
Demographic Questions 
  
1. How old are you currently? What is your date of birth? 
2. What is your current marital status? 
1. Never married 
2. Divorced 
3. Widowed 
4. Have a partner but not married 
5. Married 
3. What is your current living situation? 
1. Live alone 
2. Live with partner or spouse 
3. Live with a relative, friend, or roommate 
4. Live with a group in a private residence 
5. Live in a group home 
4. What is your dominant hand? 
5. What is the highest level of education you have completed? 
6. What was your longest-held career? 
7. What is your current height and weight? 
8. Have you ever been diagnosed with a sleep disorder (e.g. parasomnia, REM sleep 
disorder, etc.)? 
9. Have you ever been diagnosed with obstructive sleep apnea (OSA)? 
10. Have you ever been diagnosed with arthritis? 
11. Have you ever been diagnosed with cardiovascular disease (e.g. a-fib, cardiac bypass, 
pacemaker, etc.)? 
12. Have you ever been diagnosed with a neurodegenerative disease (e.g. mild cognitive 
impairment, Alzheimer’s Disease, Parkinson’s Disease, dementia, etc.)? 
13. Have you ever been diagnosed with cerebrovascular disease (e.g. stroke, cerebral infarct, 
aneurysm, etc.)? 
14. Have you ever been diagnosed with diabetes? If so, what type? 
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15. Have you ever had a heart attack or cardiac arrest? 
16. Have you ever had a traumatic brain injury (TBI)? 
17. Have you ever been diagnosed with high cholesterol? 
18. Have you ever been diagnosed with high blood pressure? 
19. Have you ever had seizures or been diagnosed with a seizure disorder? 
20. Have you ever been diagnosed with thyroid disease? 
21. Have you ever been diagnosed with a developmental disability? 
22. How would you rate your average pain level from 0 (no pain) to 10 (the worst pain) over 
the last month? 
23. Have you ever been prescribed any medications? If so, what are they and what is the 
dosage? 
24. Do you currently smoke cigarettes? If so, how many: 
1. None 
2. 1 cigarette to less than ½ a pack a day 
3. ½ pack to less than 1 pack a day 
4. 1 pack to less than 1 ½ packs a day 
5. 1 ½ packs to 2 packs a day 
6. 2+ packs a day 
25. Have you ever tried to quit smoking? 
26. How often in the past three months have you had an alcoholic beverage? 
1. Never 
2. Less than once a month 
3. About once a month 
4. About once a week 
5. A few times a week 
6. Daily or almost daily 
27. Have you ever been addicted to a substance of any kind? If so, what was it and when was 
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